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Consensus is lacking on early diagnostic criteria and the exact symptoms of Alzheimer’s 
disease (AD).  A new, in-office test may help physicians detect the early symptoms of 
AD, based upon new National Institute of Aging (NIA) criteria.  However, a gap exists in 
knowledge regarding physicians’ current use or intent to use the new protocols. 
Choreographing the descriptive AD terminology in the Diagnostic and Statistical Manual 
of Mental Disorders IV-TR and the International Classification of Diseases (ICD-10) is 
recommended.  Thus, the purpose of this study was to understand possible contributing 
factors to physician's use or intent to use of the new NIA's diagnostic protocol.  Data 
collected from 55 clinicians within 2 Northern California counties were analyzed using a 
bivariate test.  The 2 dependent variables were physicians’ use of, or intent to use, the 
NIA protocol; the 6 independent variables were number of years since graduating from 
medical school, area of specialty, percentage of patients over age 60 years, physician's 
gender, age, and knowledge about AD, as indicated by performance on the Alzheimer’s 
Disease Knowledge Scale.  The results of regression analyses indicated no statistical 
significant associations between the variables of interest (p ≥ .05).  This study is a first 
attempt at understanding physician attitudes toward, and usage patterns of, an important 
new in-office tool for early detection of AD.  Further research using a larger sample size 
to increase power is needed.  These findings have implications for positive social change 
by promoting an earlier detection of Alzheimer's disease, underscoring the need for 
additional training, and revising the terminology used in clinicians’ desktop references.  
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Chapter 1: Introduction to the Study  
Introduction 
 Dementia of the Alzheimer’s disease (AD) type is reaching epidemic proportions 
globally Lindesay et al. (2010).  Awareness of AD, early recognition of AD, and 
increased research on this type of dementia are causing this life-changing disease to rise 
as a significant concern and a healthcare priority Lindesay et al. (2010). Lindesay et al. 
(2010) reported that some physicians still use the term senile dementia, which contributes 
to the fallacy that dementia is a natural progression that comes with age. AD is not a 
normal part of aging. Researchers have identified a need to improve general practitioners’ 
and primary care providers’ skills in diagnosing AD patients, early diagnosis of 
dementia/AD, and referrals for additional evaluation of patients’ symptoms (Lindesay et 
al., 2010; Schoenmakers, Buntinx, & Delepeleire, 2009).  
There is a gap in knowledge regarding physicians’ knowledge and use of the 
National Institute of Aging (NIA) criteria for all-cause dementia. Diagnostic tests within 
the office for the early detection of AD, such as the NIA criteria, are needed for the 
accurate diagnosis of early AD. These new criteria are described and discussed in 
Chapter 2. The purpose of this study was to explore the correlations between physicians’ 
background characteristics and knowledge of AD and their intention to adopt or not to 
adopt the new criteria. 
Chapter 1 includes a brief introduction, review of background to the research 
subject, discussion of the problem statement, purpose of the study, identifying the 




study, definitions, assumptions, scope, delimitations, limitations and the significance of 
the research.  
Background 
 Leifer (2009) reported that patients and/or family members caring for loved ones 
who exhibit symptoms suggestive of AD tend to seek help initially from their primary 
care physicians (PCPs). PCPs must be aware of AD symptoms and should screen aging 
patients for AD. In Leifer’s study, family doctors (73%) and internists (11%) were the 
first physicians consulted regarding the concern about AD.  After reporting symptoms to 
their family doctors, 62% of patients with AD remained undiagnosed (Leifer, 2009).  
 AD is expected to become more prevalent as the elderly population in the United 
States increases. By the year 2040, more than 80 million individuals in the United States 
will be affected by AD (Forlenza, Diniz, & Gattaz, 2010; Leifer, 2009). A meta-analysis 
conducted in 2009 indicated the approximate prevalence of AD in the United States 
increased 1% at 65 - 69 years of age to 13 - 17% at 85 - 89 years of age and 24 - 31% at 
90 - 94 years of age (Leifer, 2009).  
            Healthcare providers use AD as a diagnostic term or way of labeling or even 
attaching a disease term to patients and AD is only one of many forms of dementia 
(Bassil & Grossberg, 2009). (The other terminology and use of forms for AD are 
discussed in Chapter 2.) According to Jack et al. (2011), widely used criteria for the 
clinical diagnosis of AD were established in 1984 by the National Institute of 
Neurological Disorders and Stroke (NINDS) and the Alzheimer’s disease and Related 




criteria, there have been many advances in AD research, which have led to new 
diagnostic techniques and thus to three stages for the classification of AD (Jack et al., 
2011). These improvements in diagnostic testing, and a better understanding of 
pathology, have generated greater understanding of AD than is reflected in the NINDS 
and ADRDA criteria (Jack et al., 2011).  
 Over the past quarter century, various tests such as use of imaging equipment 
have been used to detect AD. Research is ongoing concerning imaging techniques and the 
use of biomarkers to detect AD at the earliest stage possible. Psychological testing has 
been accomplished through various tests as well as memory recall evaluations. The 
evaluation of the patient’s medical history remains a central part of the AD evaluation 
process.  
 Yet, according to Jack et al. (2011), recent studies indicated that the early 
detection of AD does not require expensive imaging equipment or other equipment that 
evaluates cognitive domains beyond memory recall.  If, formal cognitive testing of AD is 
not feasible, then cognitive functions can still be assessed through an in office test. For 
example, the clinician can ask the patient to learn an address during the interview and 
then ask the patient to recall the address a few minutes later. Or the clinician can ask the 
patient to name four items (e.g., a notepad, a stapler, a telephone, and a pen), place them 
in various locations around the room, and later ask the patient to recall the location of the 
items and their names. Additionally, Mini-Cog state exams and computer programs such 
as the Computer-Administered Neuropsychological Screen for Mild Cognitive 




evaluate patients for AD Jack et al. (2011).  These examples are in office exams for early 
detection of AD and may lead to other healthcare tests authorized by the provider when 
assessing a patient using the new NIA AD criteria. 
 The new NIA AD criteria may be used to detect AD in the early stages of the 
disease process.  Central to these new evaluation criteria are (a) a history taking from 
both the patient and a knowledgeable informant, and (b) an objective cognitive 
assessment, which takes the form of either a bedside mental status exam (see the previous 
paragraph for an example) or neuropsychological testing and a combination of two or 
more cognitive or behavioral criteria Jack et al. (2011).  What is not known is how 
providers’ might adapt their knowledge, attitudes, and behaviors (KAB) to the new NIA 
AD diagnostic criteria (Aday & Cornelius, 2006).   
Upon a noticeable decline in cognitive function and performance can not be 
reasonably explained by a known disorder, then a neuropsychological test is indicated 
after an examination of patient history and mental status cannot provide a diagnosis and 
suspicion of cognitive impairment is detected Jack et al. (2011).  The cognitive or 
behavioral impairment of two or more domains constitute a diagnosis of all-cause 
dementia:  Core clinical criteria.  There are five domains which frame a diagnosis of AD 
and include:  impaired ability to acquire and remember new information, impaired 
reasoning and handling of complex tasks, impaired visuospatial abilities, impaired 
language functions, and changes in personality from which two or more are indications of 







There is no consensus on the exact symptoms of AD that GPs can use to diagnose 
early, middle, and late stage AD in their patients. Research indicated that as of yet, no 
studies have been conducted to explore physicians’ use or willingness to use the new NIA 
AD criteria (Jack et al., 2011).  
In this quantitative study, I put forth the hypothesis that few physicians are aware 
of the new NIA diagnostic criteria for AD, and those who are aware may or may not use 
them. Inconsistencies and gaps in the literature over the past 8 years identify gaps in 
physicians’ accurate recognition of the early signs and symptoms of AD, misuse of the 
phrase Alzheimer’s disease to describe a condition in a living person (literature indicates 
that a diagnosis of AD is conducted at autopsy and discussed further in Chapter 2). Use 
of the new NIA criteria may help physicians detect the early signs of AD to align 
treatment plans more accurately and quickly to address the patients’ level of needs.  
While the NIA AD protocol has not been evaluated by clinicians (Jack et al., 
2011), researchers and clinicians have agreed that a test (e.g., the NIA protocol) is needed 
to detect the early symptoms of AD and should be used by healthcare providers as an 
effective means of detecting AD in early stages (Christensen & Lin, 2007). In this study, 
I will explore correlations between (a) physicians’ background characteristics and 





 The results of this study has the potential for effecting social change by providing 
physicians’ a means for early detection of AD in an office setting and streamlining 
treatment plans to precisely address patients’ level of needs. In other words, patients 
could receive earlier access to healthcare options for treating their symptoms and 
activation of insurance benefits for the treatment of AD symptoms.  The way AD is 
diagnosed today physicians’ depend on the Mini-Cog state exam and similar tests to 
evaluate cognitive status.  Nevertheless, that may cause the disease to be underreported 
and misdiagnosed. The U.S. Preventive Services Task Force (USPSTF)) found 
insufficient data to recommend for or against routine screening for dementia in those 
aged 65 and over (Boustani, Peterson, Harris, & Lohr, 2003).  
The results of this study may also advance current knowledge of the new 
diagnostic criteria for AD. It may advance physicians’ knowledge of AD, earlier 
diagnosis of AD and treatments of associated symptoms, and identify the exact criteria 
doctors use to diagnose patients presenting with AD symptoms, and possibly change their 
attitude toward using the new NIA early detection criteria. The discussion in Chapter 2 
will address the importance of early detection of AD and the need to use the NIA criteria.  
Purpose of the Study 
In January 2010, President Obama endorsed the National Alzheimer’s Project 
Act. The Act is focused on improving AD research and services at all levels, as well as 
accelerating treatments to abate AD. The purpose of this research investigated 
physicians’ use of the NIA protocol through a set of two primary research questions on 




intention to use, or intention not to use the NIA criteria for all-cause dementia and the 
early detection of Alzheimer’s disease. The data collected will be useful for descriptive 
and inferential statistical analysis to then examine the data, which may or may not 
authenticate the study’s hypotheses.  
The independent variables in this study were the number of years since graduating 
from medical school, area of specialty, percentage of patients over age 60 years, 
physician gender, physician age, and knowledge about AD, as indicated by performance 
on the Alzheimer’s Disease Knowledge Scale (ADKS). In this study, there were three 
dependent variables (represented by the three primary research questions): use of the NIA 
protocol, intention to use the NIA protocol, and intention not to use the NIA protocol. 
The research questions described in this chapter and Chapter 3 may identify correlations, 
which will be discussed further in Chapters 4 and 5.  
Research Questions and Hypotheses 
The identified gaps are represented as three dependent variables and in turn 
represent two main research questions and hypotheses. Each main research question has 
six subquestions that relate directly to the independent variables in this study and that 
correspond to the survey instrument.  The two primary research questions and associated 
subquestions are as follows: 
Research Question 1: Are a physician’s background characteristics and 
knowledge associated with the physician’s use of the National Institute on Aging 




Subquestion 1A: Is the number of years since a physician graduated from medical 
school associated with that physician’s use of the NIA criteria for the detection of 
AD? 
H0A: The number of years since a physician graduated from medical 
school is not associated with that physician’s use of the NIA criteria for 
the detection of AD. 
Ha1A: The number of years since a physician graduated from medical 
school is associated with that physician’s use of the NIA criteria for the 
detection of AD. 
Subquestion 1B: Is a physician’s area of specialty associated with that physician’s 
use of the NIA criteria for the detection of AD? 
H01B: A physician’s area of specialty is not associated with that 
physician’s use of the NIA criteria for the detection of AD. 
Ha1B: A physician’s area of specialty is associated with that physician’s 
use of the NIA criteria for the detection of AD. 
Subquestion 1C: Is the percentage of patients over the age of 60 years in a 
physician’s practice associated with that physician’s use of the NIA criteria for 
the detection of AD? 
H01C: The percentage of patients over the age of 60 years in a physician’s 
practice is not associated with that physician’s use of the NIA criteria for 




Ha1C: The percentage of patients over the age of 60 years in a physician’s 
practice is associated with that physician’s use of the NIA criteria for the 
detection of AD. 
Subquestion 1D: Is a physician’s gender associated with that physician’s use of 
the NIA criteria for the detection of AD? 
H01D: A physician’s gender is not associated with that physician’s use of 
the NIA criteria for the detection of AD. 
Ha1D: A physician’s gender is associated with that physician’s use of the 
NIA criteria for the detection of AD. 
Subquestion 1E: Is a physician’s age associated with that physician’s use of the 
NIA criteria for the detection of AD? 
H01E: A physician’s age is not associated with that physician’s use of the 
NIA criteria for the detection of AD. 
Ha1E: A physician’s age is associated with that physician’s use of the NIA 
criteria for the detection of AD. 
Subquestion 1F: Is a physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, associated with that 
physician’s use of the NIA criteria for the detection of AD? 
H01F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is not 





Ha1F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is associated 
with the physician’s use of the NIA criteria for the detection of AD. 
Research Question 2: Are a physician’s background characteristics and knowledge 
associated with the physician’s intention to use the National Institute on Aging (NIA) 
criteria for the detection of Alzheimer’s disease (AD)?   
Subquestion 2A: Is the number of years since a physician graduated from medical 
school associated with that physician’s intention to use the NIA criteria for the 
detection of AD? 
H02A: The number of years since a physician graduated from medical 
school is not associated with that physician’s intention to use the NIA 
criteria for the detection of AD. 
Ha2A: The number of years since a physician graduated from medical 
school is associated with that physician’s intention to use the NIA criteria 
for the detection of AD. 
Subquestion 2B: Is a physician’s area of specialty associated with that physician’s 
intention to use the NIA criteria for the detection of AD? 
H02B: A physician’s area of specialty is not associated with that 
physician’s intention to use the NIA criteria for the detection of AD. 
Ha2B: A physician’s area of specialty is associated with that physician’s 




Subquestion 2C: Is the percentage of patients over the age of 60 years in a 
physician’s practice associated with that physician’s intention to use the NIA 
criteria for the detection of AD? 
H02C: The percentage of patients over the age of 60 years in a physician’s 
practice is not associated with that physician’s intention to use the NIA 
criteria for the detection of AD. 
Ha2C: The percentage of patients over the age of 60 years in a physician’s 
practice is associated with that physician’s intention to use the NIA 
criteria for the detection of AD. 
Subquestion 2D: Is a physician’s gender associated with that physician’s intention 
to use the NIA criteria for the detection of AD? 
H02D: A physician’s gender is not associated with that physician’s 
intention to use the NIA criteria for the detection of AD. 
Ha2D: A physician’s gender is associated with that physician’s intention to 
use the NIA criteria for the detection of AD. 
Subquestion 2E: Is a physician’s age associated with that physician’s intention to 
use the NIA criteria for the detection of AD? 
H02E: A physician’s age is not associated with that physician’s intention 
to use the NIA criteria for the detection of AD. 
Ha2E: A physician’s age is associated with that physician’s intention to 




Subquestion 2F: Is a physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, associated with that 
physician’s intention to use the NIA criteria for the detection of AD? 
H02F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is not 
associated with the physician’s intention to use the NIA criteria for the 
detection of AD. 
Ha2F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is associated 
with the physician’s intention to use the NIA criteria for the detection of 
AD. 
Theoretical Framework for the Study 
Rogers’s (2003) diffusion of innovations (DOI) theory was chosen as the 
theoretical framework for this study because historically, his theory has been used to 
better understand the dissemination and implementation of interventions specifically 
within the healthcare community such as interventions for autism, HIV/AIDS, substance 
abuse, and conduct disorder (Dingfelder & Mandell, 2010). Rogers’s DOI theory 
concentrates on describing how, why, and at what rate new technologies spread through 
social systems (Dingfelder & Mandell, 2010). The diffusion of innovation is the process 
by which a new practice or idea is vetted over time with collaborative members of a 




The survey instrument explored three dependent variables exploring knowledge, 
attitudes, and behaviors (KAB) (KAB; Aday & Cornelius, 2006).  The KAB theoretical 
approach may help explain data and responses, for example, when a respondent selects 
either an “other” response or adds a narrative response in the survey instrument then the 
response may fit into one of the three categories of knowledge, attitudes, or behaviors 
(Aday & Cornelius, 2006).  A detailed explanation of Roger’s (2003) Diffusion of 
Innovations (DOI) theory and the theoretical application of both DOI and KAB to this 
research are presented in Chapter 2.  A discussion of the application of DOI theory and 
KAB survey design to this study is discussed in Chapter 2.  
In Figure 1, I adapted a figure from a study that explored the implementation of 
an autism intervention within the DOI framework (Dingfelder & Mandell, 2011).  This 
study’s use of the DOI theory is similar to mine, and I see the NIA protocol as analogous 
to the autism intervention. Figure 1 is an illustration of DOI theory as it was used in this 
study to explore how an innovation or new idea—in this case, implementing the new NIA 
criteria for all-cause dementia and early detection of AD—might be perceived by 
physicians/clinicians. DOI theory is well suited for exploring physicians’ knowledge and 
use patterns related to the NIA criteria for all-cause dementia and early detection of AD 
because it offers a logical approach to implement the use of changes in healthcare, i.e., 
breast cancer treatment and procedures for implementing new procedures as discussed in 





(New NIA Early  
detection of AD criteria) 
Adoption Implementation Maintenance 
Key Terms: 
1.  Innovation:  an idea, practice or object that is perceived as new by an individual or 
organization. 
2.  Innovation-decision process:  the process by which an individual or organization passes 
from (1) initial awareness of an innovation to forming attitudes about and deciding to 
adopt or reject the innovation, to implement and preliminary use, to consistent and 
committed use. 
3.  Dissemination:  targeted strategies to make potential adopters aware of an innovation 
and encouraged to adopt it. 
4.  Adoption:  commitment to begin using the innovation. 
5.  Implementation:  when an individual or organization puts an innovation to use. 
6.  Maintenance:  the degree to which an innovation in continued over time, particularly 
after attempts to diffuse the innovation end (Also known as “sustainability”). 
 
Figure 1. DOI theory applied to the NIA criteria. Modification of figure from “Bridging 
the Research-to-Practice Gap in Autism Intervention: An Application of Diffusion of 
Innovation Theory,” by H. Dingfelder and D. Mandell, 2011, Journal of Autism & 




Nature of the Study 
The study was a quantitative, cross-sectional survey designed to examine 
physicians’ use patterns of the NIA criteria for all-cause dementia and the detection of 
AD. Via an online survey instrument, I gathered data from physicians responsible for 
evaluating patients with signs of AD.  The survey instrument contained items designed to 
collect data related to the three primary research questions (RQs) and associated 
subquestions based on KAB theory.  The third research question was ultimately removed 
the purpose for removing the third RQ is discussed in Chapter 4.  The three dependent 
variables (a) current use of the NIA protocol, (b) intention to use the NIA protocol, and 
(c) intention not to use the NIA protocol).  Again, (c) representing the third research 
question was removed as the question and results were the inverse of RQ 2 or (b).  The 
six independent variables (years since graduating from medical school, area of specialty, 
percentage of patients age 60 years and older, physician age, physician gender, and 
knowledge of AD).  The six independent variables may or may not have any noticeable 
relationship to use of (or intention to use/not use) the NIA protocol, but were considered 
for the purpose of exploring potential correlations to the dependent variables. Results 
from the survey instrument were expressed as percentages; descriptive and inferential 
analyses of the data are discussed in Chapter 3 and Chapter 4. 
 Data was collected from qualified, voluntary, respondents via the survey 
instrument. The data was statistically analyzed via the odds ratio, chi square, and P value 





Alzheimer’s disease (AD): A terminal disease without known etiology, treatment, 
or cure, causing significant decline of cognitive skills, psychomotor skills, and primarily 
affecting those age 65 years old and older (Forlenza et al., 2010).  
Amyloid beta (Abeta): A neurotoxic neuron that negatively affects brain tissue; 
widely accepted as the main biologic suspect in AD, causing early onset memory loss 
and/or death (Tiedeman et al., 2011).  
All-cause dementia: Cognitive or behavioral impairment that involves a minimum 
of two domains, such as impaired ability to acquire and remember new information, 
impaired reasoning and handling of complex tasks, impaired visuospatial abilities, 
impaired language functions, and/or changes in personality (Frantz, 2011). 
Classical Alzheimer’s disease symptoms (CADS): The preclinical stage wherein 
the person demonstrates frequent memory loss (e.g., poor recognition of immediate 
family members, loss of appetite, lack of interest in social activities). A condition of a 
person alive with a combination of documented signs found in current literature 
describing dementia such as lack/loss of memory, loss of cognitive skills, as well as 
decreased psychomotor skills, and demonstrating early stages of what current literature 
describes as AD. Unlike what has also been referenced in some literature in specific 
reference to patients currently diagnosed with AD to describe the cause of death also 
described as preclinical AD by the Alzheimer’s Association (Frantz, 2011).  
General practitioner (GP): A licensed medical doctor who may have limited 




symptoms, unlike a gerontologist (Schoenmakers et al., 2009). 
International Classification of Diseases (ICD): ICD-10 was endorsed by the 43rd 
World Health Assembly in May 1990 and came into use in World Health Organization 
(WHO) Member States in 1994. The classification is the latest in a series that has its 
origins in the 1850s. The International Statistical Institute adopted the first edition, 
known as the International List of Causes of Death, in 1893. WHO took over the 
responsibility for the ICD at its creation in 1948 when the Sixth Revision was published 
and included causes of morbidity for the first time.  The World Health Assembly adopted 
WHO Nomenclature Regulations in 1967 that stipulate the use of ICD in its most current 
revision for mortality and morbidity statistics by all Member States (Centers for Medicare 
& Medicaid Services [CMS], 2012).  
Knowledge, attitudes, and behaviors (KAB) theory: KAB theory is a research 
style that has been used to explore respondents’ knowledge, attitudes, and behaviors that 
may lead to an outcome. Knowledge will be measured by right and wrong answers from 
Part 2 of the survey instrument, which will explore respondents’ knowledge of AD 
through the 30-question Alzheimer’s Disease Knowledge Test (Carpenter et al., 2008). 
Physicians’ attitudes will be assessed through the survey instrument, which will gauge 
their intent to either use or not use the NIA protocol. The examination of beliefs is 
beyond the scope of the current research, but future researchers investigating NIA 
protocol use could examine specific aspects of physicians’ beliefs. A more detailed 
illustration is seen in Table 7 in Chapter 3, in which KAB theory is aligned to 




Magnetic resonance imaging (MRI): A type of medical imaging that uses the 
characteristic behavior of protons when placed in powerful magnetic fields to make 
images of tissues and organs. Certain atomic nuclei with an odd number of neutrons, 
protons, or both are subjected to a radiofrequency pulses, causing them to absorb and 
release energy. The resulting current passes through a radiofrequency receiver and is then 
transformed into an image. This technique is valuable in providing soft-tissue images of 
the central nervous and musculoskeletal systems. Imaging techniques allow visualization 
of the vascular system without the use of contrast agents. Agents such as gadolinium are 
available for contrast enhancement but must be used with caution in patients with renal 
insufficiency (Davis, 2009). 
Mild cognitive impairment (MCI): A subjectively sensed, and objectively 
verifiable, loss of memory that may result in difficulties with word finding, naming, or 
complex skill execution; it does not generally impair a person's ability to carry out 
normal activities of daily living. Mild cognitive impairment is also known as cognitive 
impairment, not dementia (CIND), and age-associated memory impairment (Davis, 
2009). 
National Institute of Aging (NIA) criteria: New criteria for diagnosis of dementia 
due to AD. A workgroup in partnership with the National Institute on Aging and the 
Alzheimer’s Association published new criteria for the diagnosis of dementia due to AD. 
The workgroup developed three categories: (a) probable AD dementia, (b) possible AD 
dementia, and (c) probable or possible AD dementia with evidence of AD 




Neurofibrillary tangles (NFTs): Linked to AD and memory loss, cognitive 
function, and ability to care for oneself in the final stage of AD. The tangles may appear 
as mushy grey matter and are widely seen in postmortem exams of patients with 
suspected AD (Snowdon, 2003). 
Neuropil threads (NTs): A mixture of proteins that may be related to diseases 
related to aging including AD. Neuropil threads are composed of tau and Ab-amyloid 
proteins. The cellular composition of neurofibrillary tangles (NFTs) and neuropil threads 
make up the altered tau protein, while extracellular amyloid plaques consist of strings of 
Ab-peptide (Ferreira & Bigio, 2011).  
Primary care providers (PCPs): Nurse practitioners, physician’s assistants, and 
medical doctors that initially evaluate and provide healthcare for patients (Leifer, 2009).  
Quantitative MRI (qMRI): A type of tomography imaging used in a medical 
setting using powerful magnetic fields to create images of the body. The images produced 
assist in the evaluation of organs and the supporting structures of the skeleton without the 
use of contrast agents employed in other imaging techniques. Quantitative MRI has 
demonstrated robust statistical confidence in limited populations of AD patients, 
promoting the advancement of further studies using similar technology in the evaluation 
of AD (Fearing et al., 2007).  
Type of practice (TOP): Internal medicine, family medicine, osteopath, general 
practitioner, and nurse practitioner are types of medical practices that may encounter 
patients aged 60 and older (Wenger et al., 2009). I will not evaluate nurse practitioners, 




 World Health Organization (WHO): The World Health Organization is a global 
organization independently renowned for overseeing issues relating to health, guiding 
healthcare, establishing policies, monitoring health on a global level, and advising policy 
makers (WHO, 2012).  
Assumptions 
 The study population was composed of physicians in Modesto, California. The 
estimated minimum sample size will be 97 physicians in order to conduct the  bivariate 
and multivariate analysis. The population of physicians in Modesto was assumed similar 
in terms of diversity, socioeconomic status, and education to the population of physicians 
in other cities and towns in California. The study population was assumed to be treating 
populations similar to those treated by doctors in other cities and towns in California. The 
city of Modesto is within a 100-mile radius of larger cities located in Northern California 
such as San Francisco, Oakland, Sacramento, Fresno, and San Jose. The population for 
this study will be assumed to be reflective of cities within this radius, which are similar to 
Modesto in terms of healthcare, socioeconomic factors, education, culture, diversity, 
employment, and age distribution based on types of home, home values, opportunities for 
K-12 education and higher education, and access to healthcare facilities.  
 Slightly more than sixteen surveys were considered successfully completed and 
enough data was gathered to evaluate the research questions. The significance of sixteen 
completed surveys correlates to statistical model predicted as being statistically 
significant per the G*Power output needed for evaluating the smallest sample size. My 




discussed in Chapter 4.  I assumed that study subjects answered the survey in a frank and 
honest manner. I further assumed that data collected helped better explain the results in 
Chapter 4 as they may relate to both the DOI and KAB research theories. 
Scope and Delimitations 
 To date, there are no other studies, which evaluated the predictors for physicians’ 
use of the new NIA Alzheimer’s assessment protocol for the early detection of AD. An 
aim of this study was to magnify the need to assess and detect the early signs of AD. 
Literature such as the ICD-10, DSM-IV, and some professional journals do not align with 
the NIA or with researchers who have stated that AD is 100% identifiable under a 
microscope. Presently, patients are diagnosed by their doctors with a disease and labeled 
as Alzheimer’s patients.  
 This study will not directly involve patients. The inclusion of age and sex of the 
provider on the survey may lead to a correlation suggesting a particular age or sex of a 
practitioner who may or may not use the new protocol, as well as other relevant 
covariates, as illustrated in Table 1 below and discussed further in Chapter 3. For 
evaluating respondents’ level of knowledge, respondents will be scored on number of 
right and wrong answers from the ADKT consisting of 30 questions. The level of 
attitudes was evaluated via the three dependent variables. The level of behaviors was also 










for RQs 1-3 






































Note. Research theory used = DOI; evaluation methodology  = KAB; data source = 




A convenience sampling strategy was selected for this research. It was intended 
that volunteers were reflective of other physicians in Modesto, California. Convenience 
sampling was selected because the sample will be taken from one geographic area. I am 
aware that findings from this study may not reflect other states and localities, as 





 The U.S. National Institute on Aging ranked AD as the sixth most deadly disease in 
the U.S. (Tiedeman et al., 2011). The benefits of early detection and accurate diagnosis of 
AD, like many other diseases, include improved disease management and quality of life.  
This study may lead to social change by promoting awareness of the importance of early 
AD diagnosis. Accurate diagnosis may assist families in reviewing finances, legal 
planning, discussing home care and long-term care alternatives, and evaluating safety 
practices (Leifer, 2009).  This study may promote social change by encouraging 
providers to (a) implement routine procedures for the detection of possible dementia in 
primary care offices and clinics, (b) begin early diagnostic evaluations for persons 
suspected of exhibiting AD symptoms, and (c) partner with those who are likeminded to 
provide care planning at the earliest possible time following a diagnosis, and (d) 
document the diagnosis and care plan in a person’s medical record (Attea & Johns, 2010).  
 In 2010, the National Institutes of Health (NIH) announced the blueprint for the 
Neuroscience Research Initiative on the Human Connectome Project to share information 
about the structural and functional connectivity of the healthy brain using state-of-the-art 
imaging instruments, analysis instruments, and information technologies to map human 
brain function. The data from this study are expected to help develop a foundation to 
advance knowledge of how the brain changes with age and AD. This new information 
may change how providers evaluate, treat, and care for elderly patients with advancing 
stages of dementia leading to AD McNab et al. (2013). 




to promulgate NIA’s recommendations as a new gold standard. On a global scale, the 
early detection of AD may affect social change by directly improving the lives of those 
with AD and their caregivers. 
Summary 
AD of the dementia type has reached the level of an epidemic. The purpose of this 
study was to explore each of the two dependent variables through a series of research 
questions and related narrative fields (which will not be directly evaluated but may be 
helpful in explaining the data in Chapter 4) by exploring participants’ knowledge, 
attitudes, knowledge, and patterns using the NIA criteria for all-cause dementia and the 
early detection of AD. 
 Chapter 2 will identify gaps between physicians’ current use, intent to use, or 
intent not to use the NIA AD protocol (the dependent variables) through a series of three 
research questions and related narrative fields (which will not be directly evaluated but 
may be helpful in explaining the data in Chapter 4). In addition, in Chapter 2 a detailed 
review of relevant AD studies using DOI theory, KAB survey quantitative methods, and 
an in depth literature on the research topic presented.  Next,  in Chapter 3 a description of 
the research methodology that was used to frame statistical models, the pilot study and 
data collection process is presented.  In Chapter 4 the results of the pilot study were 
presented as well as the discussion of the characteristics of the sample population was 
discussed.  A comprehensive statistical analysis of the data also covered.  The final 
chapter, Chapter 5 discloses the interpretation of the data collected from Chapter 4 and 




Chapter 2: Literature Review 
Introduction 
As Baby Boomers age, an estimated 11–16 million seniors in the United States of 
America will have some form of AD (Okie, 2011). Thus, there is a need for early AD 
dementia diagnosis, and the new NIA AD diagnostic protocol needs to be explored to 
assess if physicians are using the protocols or not.  A workgroup in partnership with the 
NIA and the Alzheimer’s Association published new criteria for the diagnosis of 
dementia due to AD (McKhann et al., 2011). The workgroup developed three categories: 
(a) probable AD dementia, (b) possible AD dementia, and (c) probable or possible AD 
dementia with evidence of AD pathophysiological process. The first two are intended for 
all clinical settings, while the third was established for research purposes only (McKhann 
et al., 2011). The following discussion will outline the need for this study. 
The expense for treating current patients with AD in 2011 was reportedly $130 
billion and may top $1 trillion by 2050 in Medicare and Medicaid expenses. Comparably, 
approximately 10% of seniors between the age of 70 and older have dementia (Okie, 
2011). The significance of the growing population in terms of sheer numbers, incidence 
of AD, and expense for treating the disease by providing patients with various levels of 
activities of daily living is illustrated in Figure 2. Seniors with AD may lose their higher 
level of function requiring assistance with activities of daily living such as bathing, 
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Figure 2. Modification of a graph adapted from Alzheimer’s Association, (2012c). 2012 
Alzheimer’s disease Facts and Figures. Retrieved from 
http://www.alz.org/downloads/Facts_Figures_2012.pdf 
 
In some states, such as Minnesota, according to Okie (2011), policy change 
efforts to achieve an early AD diagnosis because in 2011 Minnesota dissuaded doctors 
from diagnosing patients with AD because of the negative consequences for the patient, 
such as suicide.  Efforts to change policies are underway to revise policies from past 
practices of dissuading doctors from diagnosing AD patients to encouraging an earlier 
diagnosis of AD through laws passed by President Obama known as the Affordable Care 
Act.  The Affordable Care Act falls inline with the new NIA AD diagnostic criteria 
suggesting doctors should inform their patients of the diagnosis, seeing the benefit of at 
last knowing what has been causing the patient problems. The lack of communication 
from the GP to the caregiver’s family was previously identified as an obstacle to 




reluctant to place a note in a patient’s record with a diagnosis of AD (Schoenmakers et 
al., 2009).  Specifically, some of the feelings patients have once they receive a diagnoses 
of AD are the shame, disgrace, humiliation, and possible stigma of having a death 
sentence. However, in contrast, the early diagnosis offers patients and their family’s time 
to prepare for the more difficult stages of AD. The candor of discussing the disease and 
providing early counseling far outweighs the negative connotations (Okie, 2011).  In 
addition, some doctors may lack specific training for evaluating and treating the elderly 
(Schoenmakers et al., 2009).   
Current projections for new cases of AD indicate by the year 2040, more than 80 
million people will be affected by AD (Forlenza, Diniz, & Gattaz; 2010; Leifer, 2009). A 
meta-analysis of the approximate prevalence of AD in the United States indicates an 
increase from 1% at 65-69 years of age, to 13% to 17% at 85-89 years of age, and 24% to 
31% at 90-94 years of age (Bassil & Grossberg, 2009). I suggest use of the phrase, 
Classic Alzheimer’s Disease Symptoms (CADS), which may be more suitable to assign a 
patient living with what is thought to be AD rather than an unfounded diagnostic term as 
AD. At this time, AD has not been absolutely diagnosed and after a patient dies, an 
autopsy can be performed to examine brain tissue. During the autopsy, the results of the 
autopsy can then be used to conclusively describe the cause of death due to AD 
(Christensen & Lin, 2007). As Okie (2011) reported, some physicians and agencies avoid 
the use of AD as the diagnosis or eliminate AD as a diagnosis from health services for the 
patient (Okie, 2011). Patients and/or family members caring for a loved one may initially 




aware of AD symptoms and should screen elderly patients for AD. Family doctors (73%) 
and internists (11%) were the first physicians consulted regarding the concern of AD. 
After reporting symptoms to their family doctors, 62% of patients with AD remained 
undiagnosed (Leifer, 2009). The medical community described and referenced AD in two 
primary resources the International Classification of Diseases (ICD) and/or the 
Diagnostic and Statistical Manual: Edition IV (DSM). The need to examine the 
utilization patterns with regard to the new NIA AD protocol exists because no other study 
to date has undertaken this task. In order to examine the utilization patters of physicians 
one must look closer at three key areas (a) a historical review of AD milestones, (b) 
examine changes in ICD-9, ICD-10, and the DSM-IV, and (c) explore what new research 
has discovered in the last 27 years in regard to AD diagnostic criteria by looking at the 
new NIA AD criteria. 
This chapter included the literature review, an explanation of the literature search 
strategy, theoretical foundation, conceptual framework, and a review of the study’s key 
variables and/or concepts.  
Literature Search Strategy 
The literature review began with a database search including EBSCO, Gale, 
Proquest, Pubmed, Medline, Sage Journals, and published dissertations hosted at the 
Walden University Library. Databases searched included, but were not limited to, 
Academic Search Complete, CINAHL Plus with Full Text, Health Sciences: A SAGE 
Full Text Collection, Heath and Medical Complete, Nursing & Allied Health Source, 




Walden Library Virtual Catalog was consistently searched for additional articles. 
Secondary sources included books specific to AD, caregiving, and books complementing 
journal articles by the same authors. Other secondary sources were leads to primary 
sources, including the American Psychiatric Association, World Health Organization 
International Classification of Diseases ICD-10, Centers for Medicare & Medicaid 
Services, and the Diagnostic and Statistical Manual of Mental Disorders. Tertiary 
Alzheimer’s organizations available on-line such as Alzheimer’s Association, 
Alzheimer’s Foundation, Alzheimer’s Foundation of America, National Institutes of 
Health, and the National Institute on Aging lead to primary sources.  
  The following keywords were used:  Alzheimer’s disease, AD, Alzheimer’s 
disease intervention programs, intervention programs for Alzheimer’s, magnetic 
resonance imaging (MRI)s for AD, training, causes of death, leading causes of death in 
the United States, old age, diseases, diseases of old age, aging process, caregiving, 
caregivers, nursing, nursing homes, symptoms of AD, causes of AD, cure for AD, 
treatment for AD, AD research, current AD research, AD studies, studies of AD, MRI 
studies of AD, AD organizations, support groups for AD, local AD support groups for 
AD, AD patients, and Alzheimer’s organizations.  
This search covered years 2007 through 2015 but concentrated on the most recent 
5 years. For this research, well over 400 sources were reviewed and only 65 were chosen 
as the foundation for this research.  No research was discovered that addressed my topic, 






Rogers’s (1985) Diffusion of Innovation (DOI) theory was appropriate for this 
research because the DOI theory frames this research in such a way to collect quantitative 
data and describe the data as to how, why, or why not, and at what rate new ideas or 
concepts are used. This is the first application of the DOI theory to specifically study 
physician knowledge, attitudes and utilization patterns of the NIA criteria for all-cause 
dementia and the application of DOI theory is well documented in other healthcare 
studies. The survey results, once applied to the DOI theory, can be used to spread new 
ideas through social systems (Dingfelder & Mandell, 2011).  
In figure 1 for example, as the DOI theory is applied to the new NIA AD 
diagnostic criteria the first two stages are self explanatory, i.e., innovation—a new idea 
(use of new NIA AD diagnostic criteria) and the second stage, innovative-decision 
process—where a practice group is committed to pilot testing the new concept.  In the 
third stage of the DOI theory, dissemination is described and applied to inform users of a 
new idea and encourage them to use the new idea, i.e., using the new NIA AD criteria.  In 
the fourth stage of the DOI theory, adoption, new users of the NIA AD criteria commit to 
using the innovation, i.e., continue using the criteria to evaluate patients for early 
diagnosis of AD.  In the fifth stage, implementation, make the use of the NIA AD criteria 
the gold standard, the standard test covered by insurance companies and used by doctors 
for the assessment of patients with signs of AD.  In the final stage, stage six is 
maintenance—is described as sustainability and implies the innovative idea was 




(Dingfelder & Mandell, 2011). 
In this case, the DOI theory is ideal because of the four primary research 
questions proposed based upon a through literature review. The DOI theory and research 
questions solicit respondents to add their specific dialog responses. This is important 
because the DOI theory speaks to assisting in description of responses as to why or why 
not and responses not listed in the survey. The DOI theory has been used to better 
understand the dissemination and implementation of interventions in diverse fields, such 
as HIV/AIDS, substance abuse, and conduct disorder (Dingfelder & Mandell, 2010). 
Glasgow et al. (2012) also used the DOI theory to address the gap between current 
knowledge and practice related to the area of dissemination. Glasgow et al. focused on 
implementing research on five specific values: rigor and relevance, efficiency, 
collaboration, improved capacity, and cumulative knowledge. Similarly, there is potential 
for an intervention plan (that may be discovered through this research and presented in 
Chapter 5) to advance physicians’ knowledge, attitudes, and behaviors for the early 
detection of AD. Because there are similarities in the use of DOI to explore new ideas, 
innovations, and specifically the implementation of new AD criteria, the DOI research 
theory was selected for this study.  
The DOI theory has a long and proven history specifically in terms of studying 
conceptual ideas and evaluating empirical evidence (Dearing, 2009). Examples of how 
the DOI theory has been resourceful in research applicable to this study are well 
documented. Aday and Cornelius (2006) reported the value and importance of using DOI 




including smoking cessation and tobacco control. The DOI research theory can also be 
applied herein.  
Glasgow et al. (2012) used DOI theory in their research approach for the National 
Institutes of Health approaches to dissemination and implementation science: current and 
future directions, which explore approaches to start and prolong effective interventions. 
Glasgow et al. reported that by closing the gap between optimal patients care and what 
patients receive, there could be an impact on patients’ health. There is an indication that 
one or more factors may lead toward an intervention that may detect and/or identify the 
early signs of AD with the new AD criteria. The research herein may identify variables as 
to why one or more groups may decline the use of the new AD criteria. Therefore, the 
DOI theory is appropriate to this study, will aid in further describing the application in 
later chapters, and may help explain data and possible correlation to social change 
applications. 
The survey instrument explores the three dependent variables through six 
subquestions and applies the Knowledge, Attitudes, and Behaviors theoretical approach 
using a modified version of the original model (KAB) theory and is simply Knowledge, 
Attitudes, and Beliefs in this quantitative survey model (Aday & Cornelius, 2006). 
Conceptual Framework 
 No one has determined or currently studied the knowledge, attitudes, and 
behaviors (KAB) of physicians with respect to the new AD protocol and extent of its use 
in clinical settings because current literature also indicates there are components strongly 




current literature. There are conflicts in the literature with the current use of the term AD 
to describe patients with AD. AD cannot be once and for all diagnosed until an autopsy is 
performed and brain tissue is examined under a microscope to accurately make such a 
diagnosis (Christensen & Lin, 2007). What continues to remain confusing is that if the 
disease cannot be definitively detected unless examined postmortem under a microscope, 
then how can a patient while alive can be labeled with AD. No detectable alignment or 
collaboration is evident between the current version/edition of the ICD and the current 
version/edition of the DSM, which physicians may reference to diagnose patients with 
AD. I will evaluate physicians’ KAB in regards to the use of the ICD, DSM, and the new 
AD criteria as resources to detect/diagnose AD in light of the NIA and Alzheimer’s 
Association new updated AD criteria after 27 years of research and release of their joint 
study.  
 In order to not over simplify the complexity or stress the enormity of the problem, 
the macro approach for describing the crux of the problem begins with the description of 
the working definition of the term dementia and drills down to the very root of the 
research. The term dementia describes a wide array of brain illnesses, AD being the most 
common form of the disease. GPs use a variety of diagnostic tools such as family reports 
about the patient and documenting changes in the patient. A Mini-Cog Assessment 
(Mini-Cog) or a Mini-Mental State Examination (MMSE) may be administered by GPs to 
evaluate a person for AD (Kamenski et al., 2009; Leifer, 2009). Leifer recommended 
using the MMSE to screen for cognitive impairment. Leifer also recommended the 




two screening instruments to evaluate a person’s cognitive abilities when screening for 
cognitive impairment. The Mini-Cog is widely accepted by GPs for the evaluation of a 
person suspected of AD. The Mini-Cog itself is easy to use, brief, and not influenced by 
education or language. The Mini-Cog uses the components of the MMSE that include 
specifically the three-item recall, testing the person for the ability to recall three words 
after roughly one minute, and a Clock Draw Test (CDT) provided in Figure 3 (Kamenski 
et al., 2009). In the CDT, the patient draws a picture of a clock with as much detail (hour 
hand, numbers 1-12 properly placed, and the current time) to assess the patient’s 
understanding of time. Researchers have not conclusively indicated the relevance of the 
MMSE and the Mini-Cog among many other similar cognitive exams used for early 
detection and early intervention whereby the social change of staving off the early signs 
or symptoms of AD would result (Kamenski et al., 2009). There is no scientific test for 
those living with AD as of yet that accurately detects and ends with a conclusive 
diagnosis of AD. Cognitive tests like these are inexpensive and offer doctors evidence to 
test the patient for other diseases. The results of the family history, MMSE, and a CDT 
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Mini-Cog were entered on a data sheet. Patients
were not told their test results at this stage but
were referred to a neurologist for retesting within
six weeks (the neurologist also remained unin-
formed as to the result of the GP’s test). As part of
his/her routine clinical examination the neurologist
performed an MMSE and a CDT using the
Sunderland method.20 All the findings were then
sent to the evaluating study centre, where the results
of the GPs’ clock-drawing part of the Mini-Cog were
subjected to a ‘control check’ by an experienced
psychiatrist. After being informed about the study’s
aim and procedures patients were asked to sign an
informed consent form. The study period was from
June 2005 to September 2006.
Test description
With the original form of the Mini-Cog a score of 0
to 3 marks is given for the recall test, one point being
given for each word remembered after the CDT. A
score of 0 or 2 is awarded for the CDT part of the test –
2 points for a correct drawing, none for a wrong one.
To obtain the full Mini-Cog score the recall and CDT
scores were combined. A score of 3 and below indi-
cates a suspicion of dementia. In most cases the
Mini-Cog takes no more than three minutes to
perform.
In contrast, with the modified colour-coded
evaluation method we gave both parts of the Mini-
Cog the sameweight, threecolours (red, yellow,green)
being used as ratings. Patients were given three
words (for example ‘book’, ‘house’, ‘flower’), which
they had to repeat. They were then asked to draw a
clock face showing all twelve numbers and with the
hands pointing to ten past eleven. When this was
done, they were asked to recall the three words.
For their clock-drawing performance patients
were awarded one of three colours – green for a
perfect clock face with all 12 numbers shown, the
number 12 correctly positioned and the hour and
minute hands pointing exactly to 11 and 10; yellow
for a good clock face with minor errors but wrongly
positioned hands; and red for a clock face with major
errors, that is, with hands missing or numbers
wrongly ordered. Figure 1 shows examples of three
different test results.
Figure 1 Examples of three different CDT results
 
Figure 3. Modification of Clock Draw Test. Adapted from Kamenski et al., (2009). 
Detection of dementia in primary care: Comparison of the original and a modified Mini-
Cog Assessment with the Mini-Mental State Examination. Mental Health in Family 




Researchers published over the past 5 years identified errors of greater than 50% 
in GP diagnosis from the results of family history, MMSE, and the CDT when diagnosing 
a patient for AD because there may be other contributing factors influencing results of 




patient for dementia-like AD. A gap exists in the standard use of results from family 
history, MMSE, and the CDT to diagnose a patient with dementia-like AD (Mangilasche 
et al., 2010).  
The World Health Assembly is the governing body for the WHO. WHO manages 
the standards for healthcare and standardizing the diagnostic classifications for all 
epidemiological findings (International Classification of Diseases, 2011). WHO revised 
and updated the International Classification of Diseases (ICD) and released the draft 
version of ICD-10 in 2011. In Chapter 5, Part III, mental and behavioral disorders are 
listed; yet, none of the F01-F09 codes includes diagnostic criteria for AD. F01 describes 
vascular dementia; F02 describes dementia in other diseases classified elsewhere; F03 
describes unspecified dementia; F04 describes amnestic disorder due to known 
physiological condition; F05 describes delirium due to known physiological condition; 
F06 describes other mental disorders due to known physiological condition; F07 
describes personality and behavioral disorders due to known physiological condition; F08 
is not listed and is omitted, and F09 describes unspecified mental disorder due to known 
physiological condition (CMS, 2012, p. 227-231).  
It is not until closer examination of code F02, dementia in other diseases 
classified elsewhere, that Alzheimer’s G30, specifically G30.9, is listed among 21 sub-
diseases such as Creutzfeldt-Jakob disease, Parkinson’s disease, and vitamin B 
deficiency. Under the heading of other degenerative diseases of the nervous system, types 
of AD are listed as AD with early onset, late onset, other AD, and AD unspecified (CMS, 




Lewy bodies, mixed dementia, Parkinson’s disease, frontotemporal lobar degeneration, 
Creutzfeldt-Jakob disease, and normal pressure hydrocephalus, which are also found in 
the DSM-IV-TR (CMS, 2012).  Arguably, coordinated consensus is lacking between the 
ICD-10 and the DSM-IV-TR for defining the diagnostic criteria and symptoms of AD, 
which GPs can in turn reference for an inferential diagnosis of AD. The DSM-IV-TR 
described and listed criteria for a diagnosis of AD as seen in Figure 4. Both the ICD-10 
and DSM-IV-TR lack consistency in cohesion and uniformity, which may lead to 
misdiagnosis or failure in the early detection of AD.  A recommendation by the medical 
community at large and with the WHO to use the ICD-10 and/or the DSM-IV-TR 
independently and/or dependently of one or the other.   
In Figure 4 (which I created to illustrate) the diagnostic code of  294.1x, 
according to American Psychiatric Association, 2000, defined as dementia of the 
Alzheimer’s type.  In figure 4, for example, if a patient presents with multiple cognitive 
defects and the manifestation is accompanied by memory impairment A(1) and one or 
more A(2) aphasia, apraxia, agnosia, or disturbance in executive functioning  may result 
in cognitive deficits.  The course of decline is characterized of symptoms such as 
presenting gradual onset and declining cognition.  Additionally, criteria from category 
A(1) and A(2) must not be due to other conditions such as:  conditions of the central 
nervous system, i.e., Parkinson’s disease, cerebrovascular disease, or neurosyphilis.  The 








Figure 4. Diagnostic Criteria for AD Per American Psychiatric Association. 
Note: Modification of a table adapted from American Psychiatric Association. (2002). 
Diagnostic and statistical manual of mental disorders IVth edition. Washington, DC: 
American Psychiatric Association.  
 
Next, I used a three-tier approach to establish the conceptual framework for the 
micro discussion for this study.  I began with a past to present approach describing three 
key areas. The three key areas include a discussion of AD from a historical approach, 
moving forward to a present understanding of AD, and discussion of an overview of 
current diagnostic criteria that are associated with AD.  The theoretical foundation is 
discussed last.  
A historical examination of AD illustrates various milestones in the historical 
research of AD. Alzheimer first discovered AD through microscopic analysis and is 




physicians now see in autopsies and document in postmortem exams as a cause of AD 
death (Snowdon, 2003). Moving forward, Snowdon conducted a longitudinal study that 
provided empirical data and learned that, while some of the nuns he studied had either 
more signs and symptoms or fewer signs and symptoms of AD, they had different 
proportions of the disease seen during autopsy. Descriptive statistics have been used to 
describe variables within various studies examining AD by such researchers as Vincent 
and Velkoff (2010) who reported that by 2030, the population older adults would be 
approximately 439 and a ratio of 1:5 will be age 65 and older. Independent variables such 
as indirect cost of caring for persons with AD amounted to approximately $144 billion 
dollars (Attea & Johns, 2010). Tiedeman et al. (2011) reported evidence that is seen in 
MRIs and could be used in later stages of AD because of the same evidence seen in the 
MRIs is also present at autopsy, all of which leads current research. Frantz (2011) listed 
the new NIA and introduced the new criteria that were previously reported. The new AD 
criteria are a revision after 27 years of scientific research and describe the stages of the 
diagnostic criteria for AD.  
Snowdon (2003) published results from his longitudinal research that focused on 
postmortem results of dementia. Snowdon included 678 Catholic nuns ranging in age 
from the mid 70s to 107 years old. Information obtained from the research included 
midlife factors, physical and mental examinations, and neuropathologic data obtained 
postmortem. Snowdon further expanded Alzheimer’s postmortem findings by confirming 




 In regards to the disease’s origin, Alzheimer encountered a 51-year-old female 
known as Auguste D. in 1906. D displayed forgetfulness, confusion, and the inability to 
speak clearly. Upon her death, Alzheimer conducted an autopsy and discovered, through 
microscopic analysis, beta-amyloid plaques and NFT, signs now used in postmortem 
exams to diagnose AD (Snowdon, 2003). 
 The Snowdon Nun Research use postmortem results and health histories. A 
limitation to his research, he selected only 10 nuns for convenience with tracking rather 
than all of the nuns over the course of his 10-year research. While nuns displayed few-to-
no symptoms of dementia before death, they had higher levels of plaques and tangles in 
postmortem exams. The nuns who displayed more empirical AD symptoms, such as 
memory loss, lack of concentration, and inability to speak, displayed a healthier brain 
upon cranial autopsy (Snowdon, 2003). An increased understanding about the relation 
between dementia and AD has grown as documentation of new patients and the 
awareness of AD grew (Christensen & Lin, 2007). The following examples and 
illustrations emphasize the importance and significance related to the selection for the 
research methods used herein. 
While dementia is the more common disease, AD is one of many categories of 
dementia. AD is a term more appropriately used postmortem (Christensen & Lin, 2007). 
Medical journals, research articles, and various publications use the term AD in the 
context of a living person to describe symptoms that can only be cited as a cause of death, 
and found in research literature again to describe a patient with the disease as a cause of 




leading cause of all deaths in United States age 65 and older. Figure 5 illustrates the 
significance of AD as a cause of death in comparison to other causes of death. By the 
year 2050, the United States population is expected to grow 42% from 310 million to 439 
million. The United States population is also expected to become much older with 
approximately a ratio of 1:5 residents being age 65 and older by 2030 (Vincent & 
Velkoff, 2010). 
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Figure 5. Common causes of death in the United States. Modification graph adapted from 
Alzheimer’s Association, (2012a). 2012 Alzheimer’s disease facts and figures. Retrieved 
from http://www.alz.org/downloads/Facts_Figures_pdf 
  
In comparison to past understanding, Alzheimer’s Association recently formed a 
joint task force with the National Institute on Aging to review and revise criteria and 
guidelines for the diagnosis of AD. There are new diagnostic criteria for AD, which could 
improve diagnosis and facilitate continued research for a cure for the disease. The 




new guidelines for the diagnosis of AD and reportedly the first update in over 27 years 
from the original published guidelines (Frantz, 2011).  
 Frantz (2011) reported the new criteria describing three stages of the diagnostic 
criteria, the first being Stage 1: Preclinical. Stage 1 Preclinical symptoms, such as 
memory loss, may be absent or difficult to detect. Pathological changes may already be 
seen using biomarker tests which measure beta-amyloid accumulation in the brain, 
indicating that AD has begun. Other examples of biomarker tests may include measuring 
tau protein levels in spinal fluid or using imaging equipment to evaluate brain shrinkage. 
Stage 2: Mild cognitive impairment may be a transitional phase between normal 
forgetfulness and memory loss associated with AD. About 50% of those with mild 
cognitive impairment develop dementia of the AD type. Of those 50%, approximately 
25% may recover or regain normal functioning over time. There is no standard 
neuropsychological test to evaluate mild cognitive impairment. Consequently, because 
there is no standardized test for mild cognitive impairment, physicians adapt existing 
tests developed for other purposes. A pattern of change in cognition, impairment of one 
or more abilities, inability to function independently, and absence of dementia may be 
indications of mild cognitive impairment. Stage 3: Dementia, is characterized by 
symptoms where memory, thinking, and cognitive abilities are so severely impaired that a 
person cannot function independently are indications the person has dementia. A 
diagnosis of AD depends on clinical signs and symptoms with tests to rule out other types 




 A diagnosis of AD with the new criteria recognizes the disease develops over 
time, starting slowly and becomes more aggressive. The criteria for a diagnosis of AD 
must include at least two cognitive domains such as memory loss, loss of executive 
function, loss of visuospatial ability, and loss of fluency with language, and behavior and 
personality change. A good example of memory loss in AD patients is seen when the 
patient attempts to learn new information and recall what to do with the new information, 
that is, stating to the patient that it is time to eat and the patient is unable to prepare to 
dine. Other examples of memory loss may include the person displaying difficulty using 
higher cognitive skills to assess situations for safety, evaluating risks of crossing the 
street, operating a vehicle, or even simple activities of daily living such as taking a bath 
and getting dressed.  
 An example of visuospatial loss may be wherein the person has trouble 
recognizing surroundings or family. An example of loss of language may be seen wherein 
the person has difficulty coming up with the right words to articulate themselves. An 
example of behavior and personality changes may be seen wherein the person might 
demonstrate changes in personality such as agitation, apathy, mood changes, or 
unacceptable social behavior.  
 The Alzheimer’s Association suggested that using biomarkers for testing patients 
for AD. Although the biomarkers are currently in the test phase and are not meant for use 
in the clinical setting, the guidelines recommend using the biomarkers with clinical 
assessments to determine if a patient might be in the early stages of AD (Frantz, 2011). 




people at a much earlier stage of AD, to find a way to delay the onset of AD symptoms 
for 5 million Americans with the disease now and projections of an additional 16 million 
in another 40 years, and to recommend protective actions that can now be taken in an 
attempt to reduce risks associated with AD (Frantz, 2011). 
Fearing et al. (2007) reported evidence that no known cause or treatment exists 
for AD. The emerging literature from research in the past 5 years reinforced that there is 
no known cause or cure for AD (Christensen & Lin, 2007). Fearing et al. stated there is a 
need for GPs to receive more geriatric training and reported that additional research is 
indicated to include the use of MRIs as part of AD screening and new terminology for 
describing AD symptoms. 
 The past diagnostic criteria for AD is described in both the ICD and DSM, 
literature and information regarding AD is updated and released by the NIA, and various 
Alzheimer’s organizations (American Psychiatric Association, 2000, Christensen & Lin, 
2007; CMS, 2012, Jack et al., 2011, McKhann et al., 2011; National Institutes of Health. 
2009). What is not known per se is physicians’ KAB on the newest criteria for AD after 
the NIA and Alzheimer’s joint effort releasing the updated criteria after 27 years of 
research and to what extent the criteria are being utilized by MDs. The research questions 
described in Chapter 1 are purposefully focused on physicians’ current level of 
knowledge, attitudes, and behaviors and evaluated through Rogers’s DOI theory. The 
rationale for the foundation of this theoretical research will extrapolate how physicians 
adapt new AD criteria by adopting or not adopting the new criteria into their practice 




The past understanding of the term AD is a standardized diagnostic category 
according to the 2012 ICD-9-CM Diagnosis Code 331.0: Alzheimer’s disease, which was 
converted in 2012 as ICD-10-CM G30.9, in which AD unspecified is used to label a 
patient with the disease and to describe a disease from which a patient died and 
found/listed on death certificates (Lakkireddy et al., 2007). Throughout the literature, the 
incongruent use of AD was discovered, ranging from the use of a person alive or the 
cause of death in other uses of the term AD. The current use of the term AD by the 
medical community states AD cannot be definitively diagnosed until an autopsy is 
performed by examining brain tissue under a microscope in order to  accurately make a 
diagnosis of AD (Christensen & Lin, 2007).  Currently, brain samples are obtained 
postmortem (Christensen & Lin, 2007).  
In January 2010, President Obama endorsed the National Alzheimer’s Project 
Act. The Act is focused on improving AD research and services at all levels, as well as 
accelerating treatments to abate AD disease. The purpose of this research is to identify 
gaps between GPs presently testing patients for early stages of AD and the new NIA AD 
criteria. While there are many professional entities that have the responsibility for 
establishing consensus on standards of practice such as WHO, I identified a gap in 
standards to detect early stages of AD. In Figure 6, guidelines published by the 
Alzheimer’s Association offer a checklist for early detection of AD entitled “Know the 
10 Signs,” offering possible detection and early signs of AD that can be observed by the 
person with the disease and/or a caregiver and reported to the physician, whereas in Table 




and is the standard of diagnosis for AD.  
Alzheimer's disease (AD) Normal aging
1.  Memory loss that disrupts daily life.  One of the most 
common signs of Alzheimer's, especially in the early stages, 
is forgetting recently learned information.  Others include 
forgetting important dates or events; asking for the same 
information over and over; relying on memory aides (e.g, 
reminder notes or electronic devices) or family members 
for things they used to handle on their own.  
What's typical?  Sometimes forgetting names or 
appointments, but remembering them later.
2.  Challenges in planning or solving problems.  Some 
people may experience changes in their ability to develop 
and follow a plan or work with numbers.  They may have 
trouble following a familiar recipe or keeping track of 
monthly bills.  They may have difficulty concentrating and 
take much longer to do things than they did before.  
What's typical?  Making occasional errors when 
balancing a checkbook.
3.  Difficulty completing familiar tasks at home, at work 
or at leisure.  People with Alzheimer's often find it hard to 
complete daily tasks.  Sometimes, people may have trouble 
driving to a familiar location, managing a budget at work or 
remembering the rules of a favorite game.  
What's typical?  Occasionally needing help to use the 
settings on a microwave or to record a television show.
4.  Confusion with time or place.  People with 
Alzheimer's can lose track of dates, seasons and the passage 
of time.  They may have trouble understanding something if 
it is not happening immediately.  Sometimes they may 
forget where they are or how they got there.  
What's typical?  Getting confused about the day of the 
week but figuring it out later.
5.  Trouble understanding visual images and spatial 
relationships.  For some people, having vision problems is 
a sign of Alzheimer's.  They may have difficulty reading, 
judging distance and determining color or contrast.  In 
terms of perception, they may pass a mirror and think 
someone else is in the room.  They may not recognize their 
own reflection.  
What's typical?  Vision changes related to cataracts.
6.  New problems with words in speaking or writing.  
People with Alzheimer's may have trouble following or 
joining a conversation.  They may stop in the middle of a 
conversation and have no idea how to continue or they may 
repeat themselves.  They may struggle with vocabulary, 
have problems finding the right word or call things by the 
wrong name (e.g., calling a watch a "hand clock").  
What's typical?  Sometimes having trouble finding the 
right word.
7.  Misplacing things and losing the ability to retrace 
steps.  A person with Alzheimer's disease may put things in 
unusual places.  They may lose things and be unable to go 
back over their steps find them again.  Sometimes, they 
may accuse others of stealing.  This may occur more 
frequently over time.  
What's typical?  Misplacing things from time to time, 
such as a pair of glasses or the remote control.
8.  Decreased or poor judgment.  People with Alzheimer's 
may experience changes in judgment or decision making.  
For example, they may use poor judgment when dealing 
with money, giving large amounts to telemarketers.  They 
may pay less attention to grooming or keeping themselves 
clean.  
What's typical?  Making a bad decision once in a 
while.
9.  Withdraw from work or social activities.  A person 
with Alzheimer's may start to remove themselves from 
hobbies, social activities, work projects or sports.  They 
may have trouble keeping up with a favorite sports team or 
remembering how to complete a favorite hobby.  They may 
also avoid being social because of the changes they have 
experienced.  
What's typical?  Sometimes feeling weary of work, 
family and social obligations.
10.  Changes in mood and personality.  The mood and 
personalities of people with Alzheimer's can change.  They 
can become confused, suspicious, depressed, fearful, or 
anxious.  They may be easily upset at home, at work, with 
friends, or in places where they are out of  their comfort 
zone.  
What's typical?  Developing very specific ways of 
doing things and becoming irritable when a routine is 
disrupted.
Table 3  The Alzheimer's Association's 10 Warning Signs of Alzheimer's Disease (Alzheimer's 
Association, 2012)
 
Figure 6.  Alzheimer’s Association’s 10 Warning Signs of Alzheimer’s Disease. Note: 
Modification of a table adapted from Alzheimer's Association, (2012e). 2012 






 Dementia of the AD type must be differentiated from the typical deterioration in 
cognitive functioning associated with aging. The onset of dementia of the AD type is 
identified by one of two subtypes, which accompany early onset or late onset. The 
definition of onset as a subset of dementia with the AD type is used if the onset occurred 
at age 65 or under, whereas the definition of late onset as a subset occurs after age 65 
(American Psychiatric Association, 2000). Figure 7 was briefly discussed in Chapter 1 
and continues here to identify the diagnostic criteria per the DSM-IV-TR. 
Diagnostic criteria for 294.10 Dementia of the Alzheimer's Type Without Behaviorial Disturbance:  if the cognitive disturbance is not accompanied by any 
clinically significant behavioral disturbance.
Diagnostic criteria for 294.11 With Behaviorial Disturbance:  if the cognitive disturbance is accompanied by a clinically significant behavioral disturbance 
(e.g., wandering, agitation).
Specify subtype:  With Early Onset:  if onset is at age 65 years or below.  With Late Onset:    if onset is after age 65 years
Coding note:  Also, code 331.0 Alzheimer's disease on Axis III.  Indicate other prominent clinical features related to the Alzheimer's disease on Axis I (e.g., 
293.83 Mood Disorder Due to Alzheimer's Disease, With Depressive Features, and 310.1 Personality Change Due to Alzheimer's Disease, Aggressive Type).
F.  The disturbance is not better accounted for by another Axis I disorder (e.g., Major Depressive Disorder, Schizophrenia).
Table 2.  Diagnostic criteria for 294.1x Dementia of the Alzheimer's Type (American Psychiatric Association, 2000).  
     (1).  other central nervous system conditions that cause progressive deficits in memory and cognition (e.g., cerebrovascular disease, Parkinson's disease, 
Huntingtons's disease, subdural hematoma, normal-pressure hydrocephalus, brain tumor)
     (2).  systemic conditions that are known to cause dementia (e.g., hypothyroidism, vitamin B12 or folic acid deficiency, niacin deficiency, hypercalcemia, 
neurosyphilis, HIV infection)
     (3).  substance-induced conditions
E.  The deficits do not occur exclusively during the course of a delirium.
A.  The development of multiple cognitive defects manifested by both
     (1).  memory impairment (impaired ability to learn new information or to recall previously learned information)
     (2).  one (or more) of the following cognitive disturbances:
          (a).  aphasia (language disturbance)
          (b).  apraxia (impaired ability to carry out motor activities despite intact motor function)
          (c).  agnosia (failure to recognize or identify objects despite intact sensory function)
          (d).  disturbance in executive functioning (i.e., planning, organizing, sequencing, abstracting)
B.  The cognitive deficits in Criteria A1 and A2 each cause significant impairment in social or occupational functioning and represent a significant decline 
from a previous level of functioning.
C.  The course is characterized by gradual onset and continuing cognitive decline.
D.  The cognitive deficits in Criteria A1 and A2 are not due to any of the following:
 
Figure 7. Diagnostic Criteria for AD per American Psychiatric Association. Note: 
Modification of a table adapted from American Psychiatric Association, (2002). 
Diagnostic and Statistical Manual of Mental Disorders IVth edition. Washington, DC: 
American Psychiatric Association; American Psychiatric Association.  
  
 The NIA described diagnostic AD criteria which updates previous AD diagnostic 




Stroke (NINDS) and the Alzheimer’s Disease and Related Disorders Association 
(ADRDA) workgroup in 1984 (Jack et al., 2011). The new NIA criteria are similar to 
diagnostic criteria found in the DSM-IV-TR (American Psychiatric Association, 2000). 
 The focus of this research will target the need for the early detection of AD. As a 
secondary outcome of this research, data may indicate the need for a team approach 
directly involving the patient, family members/caretakers, and physicians. Research is 
ongoing and offers hope. Currently, there is a need for physicians to concentrate on early 
diagnosis and treatment of AD (Christensen & Lin, 2007). Christensen and Lin stated that 
modern care of AD includes the use of screening tools and DSM-IV diagnostic criteria, 
well suited for the management of AD medications used to treat AD patients, and regard 
for the caregivers well-being. Physicians can use appropriate screening tools, DSM-IV 
diagnostic criteria, management of medications for the AD patient, and inclusion of the 
needs of the patients’ caregivers (Christensen & Lin, 2007). 
 An early diagnosis of AD may help ease tensions within the family and assist in 
explaining why one’s loved one has had a change in personality, mood, activities, and 
behavior. A physician’s early detection and diagnosis of AD may assist in prompting and 
facilitating the necessity for reviewing family finances, legal planning, discussing home 
and long-term care alternatives and evaluation of safety practices of eliminating 
automobile responsibilities (Leifer, 2009). The prompt actions of a physician to detect 
and record a diagnosis of AD may positively affect social change. By leveraging routine 
procedures for the early detection of AD in primary care offices, clinics, and beginning 




the need to partner with those that are like minded, providing care planning at the earliest 
time following a diagnosis of AD. Subsequently, this would promote the importance of 
documenting the diagnosis and care plan in the person’s medical record. In some 
instances, physicians are discouraged to document a diagnosis of AD (Attea & Johns, 
2010). 
Today, patients with AD or their loved ones oftentimes realize early on that 
something is wrong; either the patient suspects memory loss or is observed by their loved 
ones as having memory loss. At this point, problems with relationships are present almost 
90% of the time and the patient knows something is wrong. Okie (2011) suggested the 
early detection and diagnosis alleviates the stress of suspecting something else is going 
on with one’s health. Even with therapy to slow down or abate the progression of AD, the 
effective approach to deal with AD is detecting the disease as early as possible (Okie, 
2011).  
A gap in the existing standards for testing for AD dementia, the lack of early 
detection tests to diagnose AD, and the combination of an MRI prescribed as a diagnostic 
tool for assessing dementia is evident in current literature. More training for GPs is 
needed in the diagnostic tools for treating dementia AD. Universal evidence-based 
training is indicated for all disciplines at all levels for professionals and paraprofessionals 
(Gould & Reed, 2009). Fearing et al. (2007) illustrated in the Cache County Research of 
Aging close proximity of clinically diagnosed AD matching similarly diagnosed AD 
subjects with postmortem confirmation of the disease using MRI technology. Fearing et 




supports quantitative MRIs could be used in helping to diagnose AD in later stages of the 
disease process.  
As recent as 2008, researchers in France used an MRI to analyze whole-brain 
anatomy, which evaluated patients with AD with similar ages as control subjects. The 
MRI utilized a support vector machine as a means to better classify segments of whole-
brain imaging (Magnin et al., 2009). The research included a study of gray matter from 
16 patients with AD during autopsy. The researchers used resampling and statistical 
formulas extrapolating data to project robustness of the research results (Magnin et al., 
2009). Consequently, the results demonstrated nearly 95% correct classification for AD, 
the control subjects yielded a mean specificity of nearly 97%, and the mean sensitivity 
was said to be nearly 92%. The researchers stated their use of MRI and testing 
methodology could statistically detect AD and consequently assist in the early detection 
of AD (Magnin et al., 2009).  
The time and the need for a reliable test for the early detection of AD has arrived. 
Recent projections forcast that by the year 2040, more than 80 million individuals will be 
affected by AD (Forlenza et al., 2010). Current AD testing protocols do not include 
ordering an MRI for the early detection of AD because doing so is not the standard of 
care presently practiced in the United States due to the expense and lack of insurance 
approval, as it may not be medically indicated. In order for the MRI to become approved 
for the early detection of AD, the MRI could become the litmus test for the evaluation of 
AD. The need to revise current GP protocols when diagnosing dementia-like AD patients 




need to address a new combination of diagnostic standards to accurately describe patient 
symptoms is proposed, establishing a standard AD test, and possibly including an MRI in 
the early phase to detect AD as a baseline for comparison in the secondary phase of AD 
where MRIs have been most effective at detecting AD. The initial review of literature for 
the past 5 years indicates GPs missed diagnoses of AD patients. The need for this 
research may have lasting positive societal changes in the elderly wherein projections for 
AD are estimated that every 1/3 of every minute someone new develops AD. AD cases 
will significantly increase as early as 2040 or 2050 (Christensen & Lin, 2007).  
However, until further research and the scientific/medical community prescribes 
the use of MRIs as a primary tool to clinically diagnose AD patients, new research 
presents GPs with an in office diagnostic test. Jack et al. (2011) reported the criteria for 
the clinical diagnosis of AD established by the National Institute of Neurological and 
Communicative Disorders and Stroke (NICDS) and the ADRDA going back as far as 
1984. Jack et al. stated that if formal cognitive testing is not feasible, then cognitive 
functions could still be assessed. For example, the clinician can ask the patient to learn an 
address during the interview and ask the patient to recall the address a few minutes later 
(e.g., 3913 Pheasant Lane, Modesto, California). On the other hand, the clinician may ask 
the patient to name three items (e.g., a note pad, a stapler, and a pen), place them in 
various locations around the room and later ask the patient to recall the location of the 
items and recall the names of the items. The convenience of such a test does not require 




early stages of MCI, and do not typically evaluate cognitive domains beyond memory 
(Jack et al., 2011). 
Several researchers reported that there will be increased numbers of AD over the 
near future. Christensen and Lin (2007) indicated the number of people in the United 
States with AD could triple by 2050 and currently there are over 5 million with AD. The 
challenge is to discover an early diagnosis of AD before the actual onset of dementia. A 
confounding issue with discovering an early diagnosis lies within the early symptoms of 
the disease itself. Magnin et al. (2009) stated that new technology exists today offering 
quantifiable evidence that MRIs, for example, offer proof that early detection of AD 
exists possibly through whole-brain vector imaging. Forlenza et al. (2010) acknowledged 
that challenges adopting new and promising procedures are in the experimental phases, 
some yet require validation, and the massive effort to introduce new information into 
clinical practice requires refinement and operational acceptance within the health care 
system.  
AD is not observable per se; only symptoms and behaviors or signs patients 
display suggest a patient might have dementia or later stages of AD. Early signs of AD 
may go undetected for several years. Currently, research is underway to discover the 
etiology, develop accurate diagnostic tests, find effective treatment, and find a cure for 
AD (American Psychiatric Association, 2002; Christensen & Lin, 2007; Fearing et al., 
2007; Forlenza et al., 2010). 
The National Institute on Aging and the Alzheimer’s Association published new 




AD dementia, (b) Possible AD dementia, and (c) Probable or possible AD dementia with 
evidence of AD pathophysiological process. The first two categories (Probable AD 
dementia and Possible AD dementia) are intended for all clinical settings. The third was 
established for research intentions only (McKhann et al., 2011).  
The National Institute on Aging and the Alzheimer’s Association developed a 
new standard of practice for the clinical diagnosis of AD. According to the workgroup in 
cooperation with the National Institute on Aging and the Alzheimer’s Association, two 
sets of criteria were developed: (a) core clinical criteria that could be used by healthcare 
providers without access to imaging techniques or cerebrospinal fluid analysis, and (b) 
research criteria that could be used in clinical research settings that include clinical trials 
(Albert et al., 2011). This research will concentrate on the first core clinical criteria. 
Albert et al. stated that because AD is a slow and progressive disease without a defined 
onset of the disease, it is difficult for clinicians to identify transition points for individual 
patients because each patient presents different signs and symptoms or may be 
asymptomatic. What is now known about AD is that an AD patient’s doctor may not see 
a predementia phase because it is difficult to identify (Albert et al., 2011).  
For patients in the predementia phase, the workgroup recommended the term mild 
cognitive impairment (MCI) due to AD to refer to the symptomatic predementia phase of 
AD. This new criteria recommended by the National Institute on Aging and the 
Alzheimer’s Association paralleled the same criteria proposed by the International 
Working Group and assumed that it is possible to identify those individuals with AD 




dysfunction (Albert et al., 2011). Table 2 lists the standard of practice for clinical 
diagnosis of Mild Cognitive Impairment. Figure 8 illustrates the new NIA AD protocols 
which are the principle focus of this research. Figure 8 illustrates how the ICD-10 and 
DSM-IV view AD by labeling AD as Mild Cognitive Impairment rather than AD, as 





Core Clinical Criteria for the Diagnosis of Mild Cognitive Impairment  
Concern regarding a change in cognition 
 
There should be evidence of concern about a change 
in cognition, in comparison with the person's 
previous level. This concern can be obtained from 
the patient, from an informant who knows the 
patient well, or from a skilled clinician observing 
the patient. 
Impairment in one or more cognitive domains 
 
There should be evidence of lower performance in 
one or more cognitive domains that is greater than 
would be expected for the patient’s age and 
educational background. If repeated assessments are 
available, then a decline in performance should be 
evident over time. This change can occur in a 
variety of cognitive domains, including memory, 
executive function, attention, language, and 
visospatial skills. An impairment in episodic 
memory (i.e., the ability to learn and retain new 
information) is seen most commonly in MCI 
patients who subsequently progress to a diagnosis of 
AD dementia. 
Preservation of independence in functional abilities 
 
Persons with MCI commonly have mild problems 
performing complex functional tasks that they use to 
perform previously, such as paying bills, preparing a 
meal, or shopping. They may take more time, be 
less efficient, and make more errors at performing 
such activities that in the past. Nevertheless, they 
generally maintain their independence of function in 
daily life, with minimal aids or assistance. It is 
recognized that the application of this criterion is 
challenging, as it requires knowledge about an 
individual's level of function at the current phase of 
their life. However, it is noteworthy that this type of 
information is also necessary for the determination 
of whether a person is demented. 
Not demented 
 
These cognitive changes should be sufficiently mild 
that there is no evidence of a significant impairment 
in social or occupational functioning. It should be 
emphasized that the diagnosis of MCI requires 
evidence of intraindividual change. If an individual 
has only been evaluated once, change will need to 
be inferred from the history and/or evidence that 
cognitive performance is impaired beyond what 
would have been expected fro that individual. Serial 
evaluations are of course optimal, but may not be 






The criteria for Probable AD dementia: Core clinical criteria are presented in 
Figure 8. 
Figure 8. Probable AD dementia: Core Clinical Criteria. Note: Modification of a table 
adapted from McKhann et al. (2011). The diagnosis of dementia due to Alzheimer’s 
disease: Recommendations from the National Institute on Aging-Alzheimer’s Association 
workgroups on diagnostic guidelines for Alzheimer’s disease. Retrieved from 
	  	   	  	   Probable	  AD	  dementia:	  	  Core	  Clinical	  Criteria	  
	  	   	  	   Probable	  AD	  dementia	  is	  diagnosed	  when	  the	  patient	  meets	  criteria	  in	  Table	  1	  
and	  has	  the	  following	  characteristics:	  
A	   Insidious	  onset.	  Symptoms	  have	  a	  gradual	  onset	  over	  months	  to	  years,	  not	  sudden	  
or	  over	  hours	  or	  days;	  
B	   Clear-­‐cut	  history	  of	  worsening	  of	  cognition	  by	  report	  or	  observation;	  and	  
C	   The	  initial	  and	  most	  prominent	  cognitive	  deficits	  are	  evident	  on	  history	  and	  
examination	  in	  one	  of	  the	  following	  categories.	  
D	   Amnestic	  presentation:	  	  It	  is	  the	  most	  common	  syndromic	  presentation	  of	  AD	  
dementia.	  The	  deficits	  should	  include	  impairment	  in	  learning	  and	  recall	  of	  recently	  
learned	  information.	  There	  should	  also	  be	  evidence	  of	  cognitive	  dysfunction	  in	  at	  
least	  one	  other	  cognitive	  domain	  as	  described	  in	  Table	  1.	  
E	   Nonamnestic	  presentations:	  
	  	   1	   Language	  presentation:	  	  The	  most	  prominent	  deficits	  are	  in	  word-­‐finding,	  but	  
deficits	  in	  other	  cognitive	  domains	  should	  be	  present.	  
	  	   2	   Visuospatial	  presentation:	  	  The	  most	  prominent	  deficits	  are	  in	  spatial	  cognition,	  
including	  object	  agnosia,	  impaired	  face	  recognition	  simultanagnosia,	  and	  alexia.	  
Deficits	  in	  other	  cognitive	  domains	  should	  be	  present.	  
	  	   3	   Executive	  dysfunction:	  	  The	  most	  prominent	  deficits	  are	  impaired	  reasoning	  
judgment,	  and	  problem	  solving.	  Deficits	  in	  other	  cognitive	  domains	  should	  be	  
present.	  
F	   The	  diagnosis	  of	  probable	  AD	  dementia	  should	  not	  be	  applied	  when	  there	  is	  
evidence	  of	  (a)	  substantial	  concomitant	  cerebrovascular	  disease,	  defined	  by	  a	  
history	  of	  stroke	  temporally	  related	  to	  the	  onset	  or	  worsening	  of	  cognitive	  
impairment;	  or	  the	  presence	  of	  multiple	  or	  extensive	  infarcts	  or	  severe	  white	  
matter	  hyperintensity	  burden;	  or	  (b)	  core	  features	  of	  Dementia	  with	  Lewy	  bodies	  
other	  than	  dementia	  itself;	  or	  (c)	  prominent	  features	  of	  behavioral	  variant	  
frontotemporal	  dementia;	  or	  (d)	  prominent	  features	  of	  semantic	  variant	  primary	  
progressive	  aphasia	  or	  non-­‐fluentagramatic	  variant	  primary	  progressive	  aphasia;	  
or	  (e)	  evidence	  for	  other	  concurrent,	  active	  neurological	  disease,	  or	  a	  non-­‐
neurological	  medial	  comorbidity	  or	  use	  of	  medication	  that	  could	  have	  a	  substantial	  







An evaluation by the GP and/or PCP of the person reporting to said individuals 
can be clinically evaluated using the new criteria. The criteria for all-cause dementia: 
core clinical criteria and other diseases ruled out for consideration for a diagnosis of 
MCI. The use of these criteria is then necessary to follow in the continued evaluation and 
diagnosis of AD. If evidence is present for a diagnosis of probable AD dementia from 
Figure 8, then Figure 9 is invaluable to further refine a more specific diagnosis of 
probable AD dementia (Albert et al., 2011; McKhann et al., 2011). I postulate that a gap 
or incongruence exists wherein the ICD, DSM, and physicians’ knowledge of the new 
NIA protocols for early AD diagnosis are incongruent and therefore emphasize the need 
for the framework of this study including assessing their knowledge of the new NIA 
protocols, attitudes for using the protocols, beliefs and behaviors to either currently use, 
intend to use, or intend not to use the NIA new AD protocol.  
With the application of the DOI theory and KAB theory design to these research 
questions, this study will be used to explore and identify physicians’ current KAB 
directly related to the new NIA AD criteria. The social change and potential implication 
may advance the diagnostic phase of AD/CADS patients compared to singularly using 
the ICD, DSM, or other previous methods spanning the course of the last 27 years.  
Key Concepts 
 The following discussion will illustrate a connection and use for the KAB survey 




questions and methodology used for this study. There are very few researchers who 
explored the relationship(s) between physicians’ KAB (characteristics such as years since 
graduating from medical school, area of specialty, percentage of patients aged 60 and 
older, physician’s age, physician’s gender, knowledge of the new NIA protocol for early 
detection of AD, and physician’s knowledge of AD) and the physician’s use, intended 
use, or does not intend to use the new NIA AD protocol. Unlike other diseases, for 
example, guidelines about early detection of breast cancer, colon cancer, and diabetes are 
well documented. However, in a recent study, similar characteristics or for the purpose of 
this study, six independent variables (IV), years since graduating from medical school, 
area of specialty, percentage of patients aged 60 and older, physician’s age, physician’s 
gender, and physician’s knowledge of AD from a knowledge score was provided by 
completing a survey instrument (Wenger et al., 2009). In addition, Rogers’s DOI theory 
has been used to better understand dissemination, application, and implementation of 
interventions within the healthcare community such as developing interventions for 
autism, HIV/AIDS, substance abuse, and conduct disorder (Dingfelder & Mandell, 2010).  
Multiple researchers regarding AD underscored the importance and role families 
play in the support of a person with AD. The following discussion is an outline of the 
importance of families, support for the  study, and reinforces the need for continued AD 
research. Much of the scientific research presently underway is focused on discovering 
the etiology of AD and a possible cure. The rationale for this study is supported by new 
information regarding AD was released by the NIA changed how we look at the many 




 Families provide a bulk of the care for their loved ones with AD. The Alzheimer’s 
Association, a voluntary health association with more than 70 chapters nationwide, 
reported nearly 11 million American families and friends provided 12.5 billion hours of 
unpaid care for persons with AD at an estimated $144 billion dollars (Attea & Johns, 
2010). The significance of the older population, Figure 9, may indicate an increased level 
of dependency on those younger than age 65 (Vincent & Velkoff, 2010). In addition, 
Tiedeman, Kim, Flurie, Korch-Black, and Brandt (2011) stated that dementia is 
characterized by deficits covering multiple areas of cognition. Such deficits are unable to 
be explained by mere aging or a typical decline in function. Symptoms of a 
neuropsychiatric are typically present as well as neurological findings. Etiology is a 
further basis for dementia. The most common cause for dementia is AD. Other causes are 
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After 2030, the old-age dependency 
ratio continues to increase slightly 
to 37 by 2050. The youth depen-
dency ratio increases minimally 
between 2010 and 2030, from 45 to 
48, and remains stable until 2050. 
CHANGING AGE STRUCTURE 
WITHIN THE OLDER  
POPULATION
The age composition within the 
older ages is projected to change 
between 2010 and 2050. As the 
baby boomers move into the older 
age groups, beginning in 2011, the 
proportion aged 65–74 is projected 
to increase (Figure 3). The majority 
of the country’s older population 
is projected to be relatively young, 
aged 65–74, until around 2034, 
when all of the baby boomers will be 
over 70. As the baby boomers move 
into the oldest-old age category, the 
age composition of the older popula-
tion shifts upward. In 2010, slightly 
more than 14 percent of the older 
population will be 85 and older. By 
2050, that proportion is expected 
to increase to more than 21 percent. 
The aging of the older population is 
noteworthy, as those in the oldest 
ages often require additional care 
giving and support (see Table A-1 
for more detailed data on the age 
distribution).
RACE AND HISPANIC 
ORIGIN7 
While the older population is not as 
racially and ethnically diverse as the 
younger population, it is projected 
to substantially increase its racial 
and ethnic diversity over the next 
four decades. Additionally, while all 
of the race and ethnic groups will 
become older, the degree of aging 
that is projected to occur within 
each group varies greatly.
In terms of race, the share of the 
population that is White alone is 
projected to decrease by about 10 
percentage points among those 
65 years and over and by about 
9 percentage points among those 
85 years and over between 2010 
and 2050. Meanwhile, all other 
race groups are projected to see 
an increase in their shares of these 
populations. The 85 years and over 
population is less racially diverse 
than the 65 years and older popu-
lation, but it is projected to see a 
similar increase in diversity between 
2010 and 2050.
Although the older population is  
not expected to become majority-
minority in the next four decades,  
it is projected to be 42 percent  
minority in 2050, up from 20 per-
cent in 2010. Among the 85 years 
7 Race and Hispanic origin are collected ac-
cording to the Office of Management and Budget 
(OMB) 1997 guidelines. For further information, 
see Revisions to the Standards for the Classifica-
tion of Federal Data on Race and Ethnicity at  
<www.whitehouse.gov/omb/fedreg 
/1997standards.html>. Race and Hispanic origin 
are treated as two separate and distinct con-
cepts in the federal statistical system. People in 
each race group may be either Hispanic or non-
Hispanic, and people of Hispanic origin may be 
any race. This report contains projections data 
for each of five racial categories (White, Black, 
American Indian and Alaska Native, Asian, and 
Native Hawaiian and Other Pacific Islander) for 
the population in the race alone categories and 
the population that is a race group alone or in 
combination with other races. Data for the alone 
or in combination groups appear in Table A-2. 
All other sections of the report refer to each of 
the races alone and use the Two or More Races 
category to represent the population reporting 














Distribution of the Projected Older Population by Age for the United States: 
2010 to 2050
Note: Line indicates the year that each age group is the largest proportion of the older population.  
Source: U.S. Census Bureau, 2008.
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Figure 9. Distribution of Projected Older Population by Age. Modified graph 
demonstrating line for each group is expected to reach the largest percentage of older 
population specifically aged 65 and older. Adapted from “The Next Four Decades The 
older population in the United States: 2010 to 2050,”by Vincent, G. &Velkoff, V. (2010). 
Population Estimates and Projection. Retrieved from 
http://www.census.gov/prod/2010pibs/p25-1138.pdf 
 
At this time, research is advancing in the area of MRIs to detect changes in the 
brain with the anticipation that early detection of AD may lead toward earlier AD 
treatment. AD is described as the accumulation of both neurofibrillary tangles (NFT)s, 
and europil thread (NT)s, with deposits of amyloid (Abeta) protein, which serve as the 
classic signs of AD. The NFTs, NTs, and Abetas are diagnostic evidence of AD at 
autopsy (Fearing t al., 2007). 
 Fearing et al. (2007) spoke of the close proximity of clinically diagnosed AD 




MRI technology. Fearing et al. postulated that quantitative MRI (qMRI) could be used in 
helping to diagnose AD in later stages of the disease. For now, AD can be 100% 
confirmed as a diagnosis for cause of death under microscopic examination during 
autopsies, but not confirmed in the living (Christensen & Lin, 2007). While there are 
various types of dementia and treatment for symptoms of AD, AD has no cure and is a 
diagnosis of exclusions made using the DSM-IV. The International Statistical Institute 
dates back to 1893, documenting causes of morbidity.  
A review of current literature demonstrates a gap in the difference in the degree to 
which there is consensus/certainty about the diagnosis of AD after autopsy (high 
agreement/certainty) versus when the patient is alive and no brain tissue has been 
examined pathologically (lower agreement/certainty). With the advancement in research 
in recent years, a comparison of ICD-9 and ICD-10 demonstrates a minimal description 
of dementia like AD symptoms in ICD-9. In ICD-9, the term organic brain syndrome was 
associated with what we more commonly refer to as AD. Organic brain syndrome was 
coded as F-09, but with the release of ICD-10, the term organic brain syndrome was 
updated to AD. Since the release of ICD-9 and ICD-10, AD has been continually 
described as a disease within those living with AD rather than a cause of death as current 
literature describes in some peer reviewed medical journals. Whereas the CADS implies 
a patient displays or demonstrates signs/symptoms we now commonly refer to as AD, the 
revised ICD-10 describes AD as a term assigned to patients which is counter to 




stated that AD cannot be 100% confirmed as a diagnosis for cause of death until 
microscopic examination. 
 Incongruence and gaps are seen in the ICD-10 because of advancements and 
updates have been seen over the past 27 years as seen in the NIA updated report in 2011. 
The ICD-10 fails to describe the diagnostic criteria for AD by only describing other 
diseases associated within the classification of dementia. In other words, the ICD-10 does 
not address AD specifically, but rather combines AD with dementia, whereas the new 
NIA calls out in clear specificity the diagnostic criteria. AD was first listed in ICD-10 and 
revised the definition of AD as an organic brain syndrome as previously found in ICD-9. 
The lack of diagnostic criteria in the ICD creates a gap for healthcare providers. The new 
release of the DSM in 2013 intended to describe and to categorize AD as a syndrome of 
psychosis and depression previously used with AD. The ICD does list three stages of AD 
and attributes related to each of the three stages. Yet, what are absent from the ICD are 
diagnostic criteria for a differential diagnosis of AD. The DSM-IV does offer diagnostic 
criteria as described earlier; however, what is described is not consistent with the new 
criteria released by the NIA as of 2011.  
 The ICD-10 differs from the DSM-IV because the ICD-10 is a system used for 
categorizing health issues and diseases globally, provides a systematic surveillance of the 
health issues and diseases, and for making decisions about the budgeting of resources in 
other countries. In contrast, the DSM-IV is a diagnostic manual used largely by medical 
doctors such as psychologists and psychiatrists for diagnosing mental health disorders in 




the ICD-9 that AD is an outcome of growing old and previously described as organic 
brain syndrome. AD has been consistently used to label a person with AD perhaps 
because of the lack of a more definitive term (American Psychiatric Association, 2002; 
Centers for Medicare & Medicaid 2012; Christensen & Lin, 2007).  
Forlenza et al. (2010) acknowledged that there are indications for a standardized 
diagnostic test or a checklist used to diagnose AD patients and training for the medical 
profession. Alzheimer’s Association Quality Care Campaign has a number of 
professional training initiatives: improving hands-on care for people with dementia in the 
U.S.A., diagnosis and biomarkers of predementia in AD, and a reaction to Dementia 
Diagnosis in Individuals with Alzheimer’s Disease and Mild Cognitive Impairment. 
Figure 10 illustrates predictions of the widespread pattern AD may take in the coming 
years. Christensen and Lin (2007) indicated the number of people in the United States 
with AD could triple by 2050 and currently there are over 5 million with AD. In Figure 
13, the higher proportion of AD can be seen in states such as Alaska, Washington, and 
reaching as far south as Nevada. The significance of the rising numbers in AD and need 
for early identification of AD onset is of the utmost concern because of the Autopsy-
confirmed AD versus clinically diagnosed AD in the Cache County Research on Memory 
and Aging substantiate, meaning that there will be an increase of AD (Christensen & Lin, 
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 3:  Projected Changes Between 2000 and 2025 in Alzheimer’s Prevalence by State
 
Figure 10. Projected Changes Between 2000 and 2025 in AD by State. Modification of a 
figure adapted from Alzheimer’s Association, (2012b). 2012 Alzheimer’s Disease Facts 
and Figures. Retrieved from http://www.alz.org/downloads/Facts_Figures_2012.pdf 
  
The DSM-IV defined the diagnostic criteria for dementia of the Alzheimer type as 
the development of multiple cognitive incongruities to carry on day-to-day activities. The 
DSM-IV does outrank or one might say takes precedence over the ICD-10 within the 
United States of America and internationally. The DSM-IV is referenced offering 
diagnostic criteria for clinicians Activities of daily living (ADL) such as eating, dressing, 
bathing, and toileting, and learning new activities or recall previous memories such as 
names of spouses or family members of which are considered higher functioning 




illustrates a few of the ADLs provided by their caregivers.  Furthermore, a failure at these 
higher functioning psychomotor skilled activities and higher cognitive skills negatively 
affects or impedes on social and/or occupational abilities. Characteristics of dementia of 
the Alzheimer’s type displays signs of acute onset decline in daily activities, which are 
also known as ADL, and are not due to other causes of mental decline of ongoing 
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 7: Proportion of Caregivers of People with Alzheimer’s and Other Dementias 
 vs. Caregivers of Other Older People Who Provide Help with Specific Activities  





















Figure 11. Proportion of Caregivers of People with AD vs. People providing ADLs. 
Modification of a graph adapted from Alzheimer’s Association, (2012c). 2012 
Alzheimer’s Disease Facts and Figures. Retrieved from 
http://www.alz.org/downloads/Facts_Figures_2012.pdf 
  
 The Alzheimer’s Association recently formed a joint task force with the National 
Institute on Aging to review and revise criteria and guidelines for the diagnosis of AD. 
The report indicated new diagnostic criteria for AD, which could improve diagnosis and 
facilitate continued research for a cure for the disease (Frantz, 2011. The National 




Alzheimer’s Association to publish new guidelines for the diagnosis of AD, reportedly 
the first update in over 27 years from the original published guidelines (Frantz, 2011).  
 Frantz (2011) reported the new criteria describing three stages of the diagnostic 
criteria, the first being Stage 1: Preclinical. Stage 1 Preclinical symptoms such as 
memory loss may be absent or difficult to detect. Pathological changes may already be 
seen using biomarker tests which measure beta-amyloid accumulation in the brain 
indicating that AD has begun. Other examples of biomarker tests may include measuring 
tau protein levels in spinal fluid or using imaging equipment to evaluate brain shrinkage. 
Stage 2: Mild cognitive impairment may be a transitional phase between normal 
forgetfulness and memory loss associated with AD. About 50% of those with mild 
cognitive impairment develop dementia of the AD type. Of those 50%, approximately 
25% may recover or regain normal functioning over time. There is no standard 
neuropsychological test to evaluate mild cognitive impairment. Consequently, because 
there is no standardized test for mild cognitive impairment (MCI), physicians adapt 
existing tests developed for other purposes. A pattern of change in cognition, impairment 
of one or more abilities, inability to function independently, and absence of dementia 
may be indications of mild cognitive impairment with criteria seen in stage three. The 
third stage is described as dementia due to AD with characteristics and symptoms where 
memory, thinking, and cognitive abilities are so severely impaired that a person cannot 
function independently indicating the person has dementia (Frantz, 2011). These three 
stages of AD are what the NIA now use for a screening and diagnosis of AD, unlike the 




develops over time, starts slowly and becomes more aggressive. The criteria for a 
diagnosis of AD must include at least two cognitive domains such as memory loss, loss 
of executive function, visuospatial ability, and loss of fluency with language, and 
behavior and personality. Examples of memory loss may include the person having 
difficulty learning new information and/or executive functions wherein the person may 
have difficulty evaluating safety risks or planning meals. An example of visuospatial loss 
may be wherein the person has trouble recognizing surroundings or family. An example 
of loss of language may be seen wherein the person has difficulty coming up with the 
right words to articulate themselves or uses multiple words to describe a roll of paper 
towels rather than just saying paper towel. An example of behavior and personality 
changes may be seen wherein the person might demonstrate changes in personality such 
as agitation, apathy, mood changes, or unacceptable social behavior.  
 The Alzheimer’s Association report suggested using biomarkers for testing patients 
for AD. Although the biomarkers are currently in the test phase and are not meant for use 
in the clinical setting, the guidelines recommend using the biomarkers with clinical 
assessments to determine if a patient might be in the early stages of AD (Frantz, 2011). 
The overarching hope with the new diagnostic criteria for AD is to help better identify 
people at a much earlier stage of AD, to find a way to delay the onset of AD symptoms 
for 5 million Americans with the disease now and projections of an additional 16 million 
in another 40 years, and recommend protective actions we can take now in an attempt to 




Alzheimer discovered the very first case of AD over 100 years ago. Since the first 
discovery of AD to the present time, run rate projections mirror numbers close to or at 
epidemic proportions to the point, some may say AD has reached the scale of a 
pandemic. Like many pandemics of the past, AD lacks an accurate etiology, lacks 
consensus on diagnostic criteria, and lacks a treatment to cure the disease. Researchers 
continue to study AD with anticipation of discovering an accurate test to detect AD. 
Progress has been seen from various diagnostic exams such as mental exams, MRIs, 
various biomarkers being studied to identify AD.  
These efforts and many others are all in an attempt discover the cause of AD and 
to develop a cure for AD. All known attempts to cure AD have failed to date, but some 
prescription medications do allow the patient with AD a brief and better quality of life 
before succumbing ultimately to AD. These examples and many other examples of 
research are all in a massive effort to find the cause and cure for the deadly disease. The 
true weakness for researchers lies only in the inability to identify the etiology and find a 
cure for AD. The strength seen in AD research thus far is the vast amounts of research 
dollars, committed researchers, and the backbone of family members keeping AD in the 
forefront of our minds each day. Unlike other research, this study stands apart by 
examining how physicians now choose or not choose to adapt the NIA’s new AD criteria. 
Forlenza et al. (2010) reported there is a need to standardize AD testing or to use a 
checklist and increase AD training for the medical profession.  
The emerging literature from research in the past 7 years reinforces the theory that 




stated there is a need for GPs to receive more geriatric training and reported that 
additional findings indicate the benefits of including MRIs as part of AD evaluations. 
This is another example of emerging research from the scientific community supporting 
the theory that as new emerging AD information surfaces.  
I will focus on the question, how are physicians incorporating new research 
evidence into clinical practice. As new results emerge, such as the new NIA AD criteria 
for AD, in the pursuit of the etiology and cure for AD so should then the approach to 
advance physician’s knowledge, attitudes, beliefs, and behaviors as they embrace the 
newfound knowledge as  using the DOI research theory. The research questions  in 
Chapter 1 are synchronous.  
The following discussion illustrates a connection and uses of Rogers DOI theory 
to help better understand the relationship to the research questions and methodology used 
for this study. The following studies are classic examples of physicians adopting and 
applying Rogers DOI theory to take data from numbers to application. For example, 
physicians set out to evaluate the effectiveness of specific interventions on the adoption 
of medical evidence as applied to clinical practices. The results from this study indicated 
that the regularity of contact to strategies for furthering the acceptance of medical 
evidence into clinical practice convincingly affects their perceived effectiveness 
(Borenstein et al., 2003). In another example, in a recent study examining the opportunity 
to optimize technology and update imaging equipment to current trends, the researchers 
applied the DOI theory (Reiner, 2012). This is an interesting study given the fact that the 




known about cost versus benefit at this time to use imaging equipment for the early 
detection of AD symptoms (McKhann et al., 2011). In another study investigating using 
surgical innovations and associated factors, which prompt lymph node biopsy for breast 
cancer, used Rodgers DOI theory to advance an intervention plan identifying sentinel 
events (Wright, Gagliardi, Fraser, & Quan, 2011).  
Therefore, the use of the DOI theory is applicable to this study by using the KAB 
theoretical approach to design the primary research questions and associated subquestions 
(Aday & Cornelius, 2006). 
Summary and Conclusions 
 The overarching theme from the literature reviewed indicates little if any 
knowledge is known about the physicians and the choice to use or not use the new NIA 
AD diagnostic protocol. The literature review demonstrates the gap in current knowledge 
regarding the utilization patterns of physicians’ use or choice to not use the new NIA AD 
diagnostic criteria. As of this time, no other researchers have investigated the utilization 
patterns of the NIA protocol by physicians. The benefits from this research will advance 
the current knowledge of the relationship between the various independent variables 
(potential predictors of use) and the dependent variable (use/non-use) by physicians’.  
Chapter 3 is a detailed discussion of the research methodology and a rationale for 




Chapter 3: Research Method 
Introduction 
The purpose of this study was to determine whether physicians’ knowledge and 
background characteristics were associated with their use of, intention to use, or intention 
not to use the NIA protocol for the early detection of AD.  I found no research that 
examined whether physicians are implementing or intend to implement the NIA’s new 
recommendations, or how their implementation or intended implementation relates to 
their knowledge and background. This chapter includes a discussion of the research 
design, rationale, methodology, and threats to validity.  
Research Design and Rationale 
The  methodology for this study was a quantitative correlational analysis of 
selected independent variables and outcomes. I explored three research questions that 
reflect  three dependent variables (current use of the NIA protocol, intention to use the 
NIA protocol, and intention not to use the NIA protocol) and six independent variables 
(years since graduating from medical school, area of specialty, percentage of patients age 
60 and older, physician age, physician gender, and knowledge of AD). Results from the 
survey instrument are expressed as percentages; descriptive and inferential analysis of the 
data is discussed.  
 Analysis of the data consists of two levels: (a) descriptive statistics describing the 
study sample and data and (b) a series of bivariate tests to identify any statistically 
significant associations of the independent variables with the dependent variables. DOI 




dependent and covariate variables directly related to this quantitative research study 
design have been identified in Chapters 1 and 2.  
 The total of correct answers on the 30-item ADKS served as a measure of 
participants’ knowledge of AD. The covariate variables aided in discussing the data in 
two ways, that is, using their descriptive or inferential statistical values. The levels of 
measurement for the variables included nominal, ordinal, interval, and ratio. The 
appropriate statistic to use for the qualitative independent variables was Spearman’s rho 
and for ordinal variables Pearson’s product-moment correlation coefficient. To avoid 
family-wise errors (Type 1) due to the large number of variables being analyzed, I 
conducted a Bonferoni adjustment to test significance and rule out random chances that 
can be problematic with multiple comparisons. The adjustment checked the p value for 
significance more stringently in order to reject the null hypothesis. For example, if one 
were testing nine independent variables and each dependent variable, and the original 
alpha level was .05 (p = .05), one would divide .05 by 9 and get p =  .0056. The threshold 
for significance was more stringent, adjusted to p = .0056, in order to reject the null 
hypothesis. A multivariate analysis was not conducted to explore possible combinations 
because none of the IVs was closely associated. A bivariate analysis was conducted to 
evaluate IVs , which, if combined, would indicate they were stronger predictors than IVs 
when linked in combination. Data collected from Part 1 of Appendix B was used in 
Chapters 4 and 5 to describe statistics, providing a descriptive statistical analysis. 
 I used Rogers’s DOI theory as a theoretical framework in my analysis of data 




I collected data through the survey for a 6-month period, which is described in detail. The 
DOI theory assisted me in determining how data from this research may be used in the 
development of an intervention plan that involves the adoption of the NIA protocol. The 
rationale for selecting a KAB survey design for this research was based largely on 
previous uses of KAB surveys in similar epidemiological research. However, the design 
of this study primarily concentrated on advancing the understanding of physicians’ 
knowledge, attitudes, behaviors, and utilization patterns in relation to the NIA criteria for 
all-cause dementia. A discussion of the exact survey methodology follows.  
The ADKS, developed in 1988 by Dieckmann, Zarit, Zarit, and Gatz, was the first 
published quiz to test the level of knowledge of Alzheimer’s disease among caregivers, 
mental health professionals, nursing home staff, and other individuals interacting with 
dementia patients. Results from the ADKS helped to develop an educational baseline to 
stimulate dialogue, clarify fallacies, and appraise other educational programs (Gilleard & 
Groom, 1994). Currently, the ADKS is one of only two published tests exploring 
knowledge about dementia with a sample population consisting of members and 
nonmembers of AD society. The ADKS is incorporated into this study to assist in 
exploring physicians’ KAB. The ADKS consists of 30 questions and is found in Part 2 of 
Appendix B.  
As previously stated, Rogers’s DOI theory was applied to better understand the 
dissemination and implementation of interventions within the healthcare community, 
such as interventions for autism, HIV/AIDS, substance abuse, and conduct disorder 




assessment study, in which the researchers applied the DOI theory. In the breast cancer 
risk assessment study, the researchers applied the results of the study and applied the DOI 
theory to develop an intervention program (Guerra, Sherman, & Armstrong, 2009). The 
application and use of DOI theory may also be helpful in further explaining the data in 
Chapter 5. 
The ADKS has been used in two other studies. The purpose of one of these 
studies (Dieckmann et al., 1988) was to determine the AD awareness of undergraduate 
students. The second study, conducted by O’Conor in 2001, was designed to determine 
an effective way of educating people about AD (Sullivan, Finch, & O’Conor, 2003). The 
ADKS is designed for use in research contexts and is capable of assessing knowledge 
about AD among laypeople, patients, caregivers, and professionals (Carpenter, Balsis, 
Otilingam, Hanson, & Gatz, 2008). The survey design for this research advances what 
Dieckmann et al. and possibly others have done, in the sense that this study focuses on 
physicians’ KAB related to the NIA Alzheimer’s diagnostic protocol. The ADKS could 
be used to explore individuals’ current knowledge of AD. The results could be 
administered again following a seminar, intervention, implementation of AD training, or 
in-service to evaluate participant’s newfound understanding of AD and/or assess the 
effectiveness of public health campaigns (Carpenter et al., 2008). 
Other designs such as a qualitative approach were considered; however, these 
designs failed to align with current research and studies discussed in Chapter 2 and would 
not have facilitated direct comparison between samples. This research proposal does 





The  methodology was a quantitative correlational analysis of selected 
independent variables and outcomes. My intention was to conduct a multivariate analysis 
following the multivariate analysis of the data from Table 3 illustrated the data analysis 
plan for this study. However, upon conducting the bivariate analysis and upon examining 
the results of the bivariate analysis I discovered no associations and concluded the 
multivariate analysis was unnecessary in the absence of significant results from the 
bivariate analysis. 
Table 3 
Priori Power Analysis to Determine Total Study Sample Size 
Exact correlation Bivariate normal model 
Options Exact distribution 
Analysis A priori: Compute required sample size 
Input Tail(s) = One 
  Correlation ρ H1 = 0.7071068 
  α err prob = 0.05 
  Power (1-β err prob) = 0.95 
  Correlation ρ H0 = 0 
Output Lower critical r = 0.4259020 
  Upper critical r = 0.4259020 
  Total sample size = 16 
  Actual power =  0.9507112 
  
Table 4 correlates the six research questions to the data analysis plan. A 
multivariate analysis may illustrate a statistically significant relationship; with the 
dependent variables, showing which independent variable may influence a physician to 
use the new NIA protocol. For example, when examining knowledge (K) from the 




the dependent variables. A possible recommendation might be theoretically indicated and 
associated with DOI theory to design an educational intervention.  
Table 4 
 Data Analysis Matrix for DOI/KAB/Alzheimer’s Study  
 RQ A, B, and 
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A recommendation for an educational intervention was discovered through the 
interpretation of the findings and discussed in Chapter 5. When I evaluated the data in 
Chapter 4, a greater sensitivity response to the questions logically indicated a need for an 




Chapter 5, in which I suggested several possible directions or areas in which research 
could continue.  
 Currently, I found no research on predictors for utilization of the NIA 
Alzheimer’s assessment protocol by primary care physicians. While perspicacious, 
existing published empirical data on physicians’ knowledge of and use of the NIA AD 
protocol require further exploration.  
Population and Sample 
The targeted population (general practice physicians, family practice doctors, and 
internal medicine physicians) for this research was selected by examining the number of 
physicians within approximately 10 listed cities in California’s Central Valley region 
using Superpages.com and information from a large medical treatment facility and Dr. 
Joseph Provenzano, DO.  Doctor Provenzano expressed an interest in helping me with 
my research topic and became instrumental in connecting me with a large medical 
treatment facility in Stanislaus County.  The selection criteria were further refined to 
Modesto and Stockton, California, which are located within Stanislaus County. Both 
Modesto and Stockton are comparable in demographics (e.g., socioeconomic status, level 
of education, income, race, sex, and access to care) to cities such as Sacramento, San 
Jose, and San Ramon. The city of Modesto has 109 family medicine practices and general 
practice surgeons listed with the local medical society. Physicians from two major 
healthcare organizations will be invited to participate in the survey: Sutter Gould Medical 




Northern California. With the use of both facilities, it should be possible to achieve the 
minimum number of respondents.  
In order to conduct the bivariate and multivariate analyses for the study, I needed 
16 subjects for each predictor variable in the multivariate model (see Table 5), for a total 
of 97 subjects for the study (see Table 6).  I will discuss my actual power analysis in 
Chapter 4 in detail. 
Table 5 
Priori Power Analysis to Determine Total Study Sample Size 
Exact correlation Bivariate normal model 
Options Exact distribution 
Analysis A priori: Compute required sample size 
Input Tail(s) = One 
  Correlation ρ H1 = 0.7071068 
  α err prob = 0.05 
  Power (1-β err prob) = 0.95 
  Correlation ρ H0 = 0 
Output Lower critical r = 0.4259020 
  Upper critical r = 0.4259020 
  Total sample size = 16 
  Actual power =  0.9507112 
  
Table 6 
Multivariate Regression Analysis to Determine Total Sample Size for Study 
Anticipated effect size (f2) 0.15 
Desired statistical power level 0.8 
Number of predictors 6 
Probability level 0.05 
Results (minimum required sample size) 97 
 
The individual predictor and total minimum sample size were calculated using the 




tailed test was selected because a one-tailed test provides more power than a two-tailed 
test and because multiple factors will be examined (Faul et al., 2009). A two-tailed test 
was rejected, given that responses to my survey questions are mostly dichotomous and I 
am not concerned about the direction of the association, as with clinical trials dealing 
with medication and therapies where adverse reactions (negative associations) are of 
interest and concern. I determined my minimum sample size to be 97. Although the 
minimum sample size is 97, I strived for a higher response rate in order to achieve a 
higher sensitivity and greater statistical value (Faul et al., 2009). 
The effect size was set at (f 2) = 0.15 (considered a medium effect size), and a 
statistical power level set at 0.8. Six predictors were identified in Table 6 and accounted 
for in the calculation to determine the minimum sample size, a probability level of 0.95, 
and standard deviation of 0.5.  
Participant Recruitment and Screening 
I initially collaborated with Sutter Gould Medical Center, and this partnership 
included the support of the medical director. I have spoken with the local chief of 
operations, and she indicated she could assist in gathering a large group of physicians to 
complete the survey instrument.  
 An invitation letter was sent to 200 potential survey participants from two of the 
109 listed practices within Stanislaus County. The invitation announced the survey and 
sought out voluntary participants. An ideal candidate for the survey was identified as 
being a physician who was involved in diagnosing persons with AD and practices within 




Appendix B, Part 1. The exclusion population consisted of those individuals removed via 
the survey instrument in this survey. The final sample size is discussed in Chapter 4. 
Online Survey Procedure 
The rationale for deploying the survey via an online format was thought to be cost 
effective and time efficient, avoided the potential for duplication of data from the same 
respondents, aided in tracking completion rates, was valuable in sending out reminders to 
complete the survey, and assisted in all attempts to achieve the appropriate sample size. 
The first part of the online survey prescreened volunteers and prevented unqualified 
respondents from continuing the survey. Unqualified candidates (those who did not select 
A for Question 1, selected a response other than A for Question 2, and selected a 
response other than B for Question 3) were directed to the exit page of the online survey. 
Disqualified volunteers were provided additional information regarding the NIA AD 
protocol as well as an explanation for why they were not allowed to proceed with the 
survey. Demographic data was collected through the survey. No identifiable information 
was collected. Qualified candidates were prompted to complete the informed consent 
form and were able to print a copy of the consent form. All parties acknowledged the 
consent form electronically. 
Respondents completed the online survey I developed and hosted by Qualtrics. 
Several opportunities were presented at the start of each section and/or at the end of each 
section for respondents to indicate whether they wanted to either exit or continue the 
survey. I utilized Qualtrics online statistical software to build my survey instrument, and 




analysis through my selected criterion using SPSS software. I coordinated my efforts 
with my contact at a large medical facility in Stanislaus County in California to launch 
my survey instrument. She and others at the facility assisted me by sending 900 
invitations via a fax to their healthcare members and invited them to participate in my 
online survey.  
Data Analysis 
Table 5 illustrates the six subquestions, the research theory behind each question, 
the data source intended to gather the data for this research, the level of measurement, the 
literature resource associated with subquestion, and intended analysis procedures.  
 The operational phase of the survey took place via notifying volunteer pool 
participants the survey was active online via an email with instructions to begin the 
online survey. The independent variables were physicians/clinicians and their responses 
to survey questions. The dependent variables were either the physicians’ use or intent to 
use of the NIA protocol. The covariate variables and confounding variables were 
uniquely defined as independent variables that may influence a study but have a 
relationship with independent or dependent data (Creswell, 2003).  
 The covariate variables for this study included demographical data such age, sex, 
type of practice, and number of years since graduating from medical school and are cross 
referenced to the survey questions. The data included were variables collected during the 
sampling/completion of the surveys. Responses from Part 2 of the survey were scored 
and compared to right and wrong responses documented by Carpenter et al. (2008). An 




scientifically proven that mental exercise can prevent a person from getting Alzheimer’s 
disease.” Data was analyzed using IBM SPSS Statistics 21. Data were screened and 
descriptive statistics used to summarize computed demographic characteristics of the 
participants and responses to Part 2 of the survey. A comparative analysis evaluated 
distributions on both independent and dependent variables to evaluate appropriateness of 
various statistical procedures. The intent was to categorize responses by gender and age 
concerning the survey instrument. A completed discussion and analysis of all data is 
further discussed in Chapter 4.  
I considered one area of investigation: to explore providers’ knowledge, attitudes 
and utilization patterns of the new NIA AD protocol investigating provider perceptions 
and opinions regarding the feasibility of incorporating the new NIA AD criteria 
recommended by the NIA and Alzheimer’s Association through responses to the two 
primary research questions and discussed next. 
Research Questions and Hypotheses 
Research Question 1: Are a physician’s background characteristics and knowledge 
associated with the physician’s use of the National Institute on Aging (NIA) criteria for 
the detection of Alzheimer’s disease (AD)? 
Subquestion 1A: Is the number of years since a physician graduated from medical 





H01A: The number of years since a physician graduated from medical 
school is not associated with that physician’s use of the NIA criteria for 
the detection of AD. 
Ha1A: The number of years since a physician graduated from medical 
school is associated with that physician’s use of the NIA criteria for the 
detection of AD. 
Subquestion 1B: Is a physician’s area of specialty associated with that physician’s 
use of the NIA criteria for the detection of AD? 
H01B: A physician’s area of specialty is not associated with that 
physician’s use of the NIA criteria for the detection of AD. 
Ha1B: A physician’s area of specialty is associated with that physician’s 
use of the NIA criteria for the detection of AD. 
Subquestion 1C: Is the percentage of patients over the age of 60 years in a 
physician’s practice associated with that physician’s use of the NIA criteria for 
the detection of AD? 
H01C: The percentage of patients over the age of 60 years in a physician’s 
practice is not associated with that physician’s use of the NIA criteria for 
the detection of AD. 
Ha1C: The percentage of patients over the age of 60 years in a physician’s 
practice is associated with that physician’s use of the NIA criteria for the 




Subquestion 1D: Is a physician’s gender associated with that physician’s use of 
the NIA criteria for the detection of AD? 
H01D: A physician’s gender is not associated with that physician’s use of 
the NIA criteria for the detection of AD. 
Ha1D: A physician’s gender is associated with that physician’s use of the 
NIA criteria for the detection of AD. 
Subquestion 1E: Is a physician’s age associated with that physician’s use of the 
NIA criteria for the detection of AD? 
H01E: A physician’s age is not associated with that physician’s use of the 
NIA criteria for the detection of AD. 
Ha1E: A physician’s age is associated with that physician’s use of the NIA 
criteria for the detection of AD. 
Subquestion 1F: Is a physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, associated with that 
physician’s use of the NIA criteria for the detection of AD? 
H01F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is not 
associated with the physician’s use of the NIA criteria for the detection of 
AD. 
Ha1F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is associated 




Research Question 2: Are a physician’s background characteristics and knowledge 
associated with the physician’s intention to use the National Institute on Aging (NIA) 
criteria for the detection of Alzheimer’s disease (AD)?   
Subquestion 2A: Is the number of years since a physician graduated from medical 
school associated with that physician’s intention to use the NIA criteria for the 
detection of AD? 
H02A: The number of years since a physician graduated from medical 
school is not associated with that physician’s intention to use the NIA 
criteria for the detection of AD. 
Ha2A: The number of years since a physician graduated from medical 
school is associated with that physician’s intention to use the NIA criteria 
for the detection of AD. 
Subquestion 2B: Is a physician’s area of specialty associated with that physician’s 
intention to use the NIA criteria for the detection of AD? 
H02B: A physician’s area of specialty is not associated with that 
physician’s intention to use the NIA criteria for the detection of AD. 
Ha2B: A physician’s area of specialty is associated with that physician’s 
intention to use the NIA criteria for the detection of AD. 
Subquestion 2C: Is the percentage of patients over the age of 60 years in a 
physician’s practice associated with that physician’s intention to use the NIA 




H02C: The percentage of patients over the age of 60 years in a physician’s 
practice is not associated with that physician’s intention to use the NIA 
criteria for the detection of AD. 
Ha2C: The percentage of patients over the age of 60 years in a physician’s 
practice is associated with that physician’s intention to use the NIA 
criteria for the detection of AD. 
Subquestion 2D: Is a physician’s gender associated with that physician’s intention 
to use the NIA criteria for the detection of AD? 
H02D: A physician’s gender is not associated with that physician’s 
intention to use the NIA criteria for the detection of AD. 
Ha2D: A physician’s gender is associated with that physician’s intention to 
use the NIA criteria for the detection of AD. 
Subquestion 2E: Is a physician’s age associated with that physician’s intention to 
use the NIA criteria for the detection of AD? 
H02E: A physician’s age is not associated with that physician’s intention 
to use the NIA criteria for the detection of AD. 
Ha2E: A physician’s age is associated with that physician’s intention to 
use the NIA criteria for the detection of AD. 
Subquestion 2F: Is a physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, associated with that 




H02F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is not 
associated with the physician’s intention to use the NIA criteria for the 
detection of AD. 
Ha2F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is associated 
with the physician’s intention to use the NIA criteria for the detection of 
AD. 
Pilot Study 
 I attempted to get four subject matter experts to serve as my expert panel and to 
review then comment on the pilot study. The expert panel members were physicians 
meeting the same qualifications described in Appendix B. The purpose of the expert 
panel served as a checks-and-balances mechanism for the survey instrument before 
conducting the pilot study.  
 I conducted a pilot study to ensure that physicians understood the questions, to 
verify the clarity of the question(s), and to check the cohesion/sequencing of the 
questions. The number of participants needed for the pilot study is estimated at between 
three and five. The respondents were asked to provide their feedback as part of their 
instructions. For example, the respondents were asked to answer each question as though 
they were answering the survey.  
 Respondents were asked to provide feedback to each question and invited to 




Comments from the pilot study were then evaluated and considered for incorporation  
when and where indicated. The pilot study will not validate the actual survey instrument. 
Rather, the pilot study provided an opportunity to make refinements based upon 
respondent feedback. The pilot study was deployed in a similar fashion as the actual 
survey instrument in the following sequence. 
 To begin, invitations to participate in the pilot study were sent to approximately 
three to five candidates. In the invitation, I asked potential participants to complete the 
pilot study and to provide feedback. The specific feedback sought from the pilot study 
respondents related to the clarity of the questions, respondents’ understanding of the 
questions and available responses, and the sequencing of the survey questions.  
 A reasonable expectation was that some candidates may not have the time or 
strong enough interest to complete all of the steps necessary to complete the pilot study. 
If two to five respondents complete the pilot study, there may be enough feedback to 
address issues such as sequencing, clarity, and overall understanding of the instrument. 
The pilot study respondents were tentatively identified as three physicians willing to 
assist pro bono.  
 Once three to five strong candidates were identified by the initial invitation, they 
received the pilot survey with instructions to answer each question as though they were 
answering the actual survey instrument. Respondents were asked to provide feedback to 
each question and invited to provide general comments about the survey itself at the 
conclusion of the pilot survey. Respondents to the pilot survey were then asked to return 




 I evaluated feedback from the pilot survey responses and received no indications 
to make any corrections to the survey. Consequently, there were no changes made or 
recommended and I shared this information with the research department at Walden 
University. I requested permission to contact the survey pool to begin my survey and 
received approval from Walden University (add the approval number here—unless it’s 
already been given elsewhere). The respondents from the pilot study were included in the 
survey pool.  
Instrumentation 
 A combination of questions from this research discussed in Appendix B and the 
addition of 30 questions from the AKDS (Carpenter et al., 2008) in totality served as the 
backbone of this survey instrument. Permission to use the AKDS was received as seen in 
the correspondence in Appendix A. The AKDS is well documented for assessing 
respondent’s knowledge of AD. The additional 30 questions assisted in assessing 
respondent’s knowledge of AD and added statistical value as related to Research 
Question 6. 
Carpenter et al. (2008) revised and increased the ADKS sensitivity to accurately 
reflect current understanding of AD. Permission was sought and received from Carpenter 
to use the 30 question ADKS within the scope of the research herein (see Appendix A). 
The appropriateness of the 30-question survey in combination with this exploration may 
further advance current knowledge of AD and possibly advance the benefits of early AD 
diagnosis.  




the ADKS indicate the scale has enough statistical sensitivity for reliability and validity. 
In the development of the ADKS, the research was conducted specifically to develop a 
survey instrument. As such, the population selected was chosen to validate the 21question 
survey instrument for Carpenter’s research and subsequent development of one 
instrument with thirty questions. Unlike Carpenter’s ADKS survey, which used a random 
half of the (n = 384) initial respondents and reduced the survey population to (n = 26) for 
the pilot study (Carpenter et al., 2008), I intend to use all of the data received after the 
data are cleaned. According to Carpenter et al. (2008), the ADKS was proctored twice to 
40 respondents and ranged in age from 22 to 87 years (M = 48.9 years, SD = 21.2), and 
their scores on the ADKS ranged from 19 to 30 (M = 24.2, SD = 2.4), indicating 
variability in the respondent’s knowledge about AD (Carpenter et al., 2008). The test-
retest interval ranged from 2 to 50 hr (M = 20.4, SD = 15.9), and the test-retest reliability 
coefficient was .81, p < .001, indicating appropriate test-retest reliability (Carpenter et al., 
2008).  
Carpenter et al. (2008) stated that validity was confirmed for the ADKS by 
calculating data from performance on the ADKS and ratings of self-reported knowledge 
about AD from the respondent pool. Data from specific groups/subgroups were 
significant, that is, for dementia caregivers, r = .46; for AD professionals, r = .39; for 
older adults without cognitive impairment, r = .41; and for undergraduates, r = 20 
(Carpenter et al., 2008). Consequently, respondents do have some 
understanding/knowledge of AD (Carpenter et al., 2008). The ADKS was used in other 




programs (Carpenter et al., 2008).  
Data Analysis 
 Data was analyzed using IBM SPSS Statistics 21. Completed surveys were 
evaluated and screened for completeness. Incomplete surveys were eliminated from the 
overall survey results. I conducted a bivariate linear regression analysis on selected 
independent variables and the outcome/dependent variables. I selected independent 
variables based on the literature and which variables hypothesized may be related to the 
outcome. The rationale for selecting specific independent and/or covariate variables as 
discussed in Chapter 2 suggested a possible independent or dependent relationship within 
the six research questions which may identify why physicians will or will not use the 
NIA protocol for the early detection of AD (Wenger et al., 2009). 
For example, one research question examines years in practice might be 
associated with the use or likely use of the protocol, and then I ran that analysis and 
evaluated the data as possible strong predictors. I did this for several independent 
variables. Then I selected the top variables with the highest statistical association or value 
and ran the analysis in a model together to see if together or a combination of them gives 
a stronger value. Next, I ran a multivariate regression analysis on my top independent 
variables and my outcomes. After running combinations of these variables, I evaluated 
the data to determine if I get a strong association value. After running various 
combinations, I tried to identify and suggest a combination, which showed the strongest 
association to potential predictors. Unfortunately, there were no significant combinations 




analysis. I will present my findings from the bivariate analysis in Chapter 4 and discuss 
the implications of the findings in Chapter 5 in detail. 
Threats to Validity 
 Consideration for both internal and external validity was evaluated. A plausible 
internal threat to internal validity was examined regarding the selection of variables. The 
expert panel and the pilot study evaluated the selection criteria to both expose and 
recommend solutions for correction. A possible threat to statistical conclusion lied in part 
with the uncertainty of reaching the totality of expected responses to the survey 
instrument. The approach taken to achieve successful completion of statistical analysis 
was achieved by conducting a Priori Power analysis. The Priori Power analysis 
mathematically calculated a minimal statistical sensitivity rate needed to achieve 
significant value for the study. The number needed is 97 respondents. At this time, I 
know of no other researcher exploring a similar topic and know of any existing threats to 
external validity.  
 There are several strengths to the current study. The ADKS originally published 
by Dieckmann et al. in 1988 consisted of a 30-item multiple-choice tool to evaluate what 
respondents know about AD. Since then, the ADKS has been used throughout research 
endeavors about AD with specific consideration for both dependent variables (e.g., 
Sullivan & O’Conor, 2011) and independent variables (e.g., Carpenter et al., 2008; 
Proctor, Martin, & Hewison, 2002). Since 1988 and to the present time, much has been 
learned and published about AD (Carpenter et al., 2008). The ADKS does not account for 




about AD. However, the ADKS was developed to address what was then currently 
known in about AD in 2008 and was considered up to date (Carpenter et al., 2008). 
Carpenter et al. acknowledged some internal consistency reliability being low and 
attributed it to the true/false response format and relatively high item difficulty indexes 
resulting in lower variances. Whereas internal threats posed similar issues again because 
the data from the ADKS study have not been validated (Carpenter et al., 2008). 
 Ethical consideration were undertaken to ensure Institutional Review Board (IRB) 
application was submitted and approved, consensus from my committee and University 
Research Review was achieved, and all documentation was either emailed or faxed to the 
IRB. Ethical consideration for survey participants was taken.  Appendix B provides an 
outline of the online survey beginning with prequalifying questions. If the participant 
does not meet the inclusion criteria for the study, they were sent to an exit screen with a 
hyperlink to where they may learn more about the newly released NIA AD criteria. I 
completed the NIH Office of Extramural Research Protecting Human Research training 
in preparation of deploying my survey instrument (Certification of training Number: 
1153705) as seen in Appendix C. 
 The participant must acknowledge they are aware of and have receipt of 
information for the informed consent before entering the survey. Participants may exit the 
survey at any time and were presented with an exit screen with a hyperlink to where they 
may learn more about the newly released NIA AD criteria. Participants’ information 
collected from the survey instrument and responses were encoded into an Excel 




protected, password protected, and stored on password encrypted external hard drive. All 
collected information and results from the survey instrument were encoded to protect 
respondents and to provide anonymity. All data were accessible via a secured and 
password protected account and accessed by the researcher and research committee. The 
data will be archived after 5 years. In my job, there are no conflicts of interest. I have no 
affiliations to any research company, group, and/or individual. 
Summary 
In this chapter I addressed the approach this research utilized to answer the 
primary research question. I will explore physicians’ knowledge, attitudes, and behaviors 
toward the NIA AD new protocols. In addition, in this chapter I discussed the research 
design, rationale, methodology, and threats to validity. In the following chapter, Chapter 





Chapter 4: Results 
Introduction 
The purpose of this study was to explore the relationship between six independent 
variables and two dependent variables. The independent variables were: the number of 
years since graduating from medical school, physicians’ area of specialty, percentage of 
patients aged 60 and older, physicians’ age, physicians’ gender, and physicians’ 
knowledge of AD. The two dependent variables were (a) current use of the NIA protocols 
and (b) intention to use the NIA protocol. This is how they appear in RQ1 and RQ2:  
Research Question 1: Are a physician’s background characteristics and 
knowledge associated with the physician’s use of the National Institute on Aging 
(NIA) criteria for the detection of Alzheimer’s disease (AD). 
 Research Question 2: Are a physician’s background characteristics and 
knowledge associated with the physician’s intention to use the National Institute 
on Aging (NIA) criteria for the detection of Alzheimer’s disease (AD). 
I examined the associations between the variables using a quantitative, 
correlational research design, as described in Chapter 3. This chapter also details the data 
analysis, such as descriptive statistics, univariate and bivariate analyses, as well as 
outcomes from each detailed analysis performed. I will discuss the expert panel review, 
the pilot study, data collection, characteristics of the study population, details of analysis, 




Expert Panel and Pilot Study 
 Before launching my pilot study and during the development of my survey, I 
sought the expertise and opinions of two clinicians, Dr. Amy Bader and Dr. Joseph 
Provenzano. My purpose in asking for their opinions was to gain insight into the pilot 
study process and eventually to obtain consensus validity of the full survey instrument. 
Neither Dr. Bader nor Dr. Provenzno participated further after providing their initial 
comments in serving as my expert panel review committee. Neither of them suggested 
changes and had similar comments that the invitation was easy to follow and the survey 
was easy to complete. I reported my findings to my committee members and to the 
Walden University Institutional Review Board. Subsequently, I was allowed to conduct 
my pilot study (IRB approval number 03-10-14-011114). 
           Participants in the pilot study included four subject matter experts, physicians who 
were similar to the participants for the main study. The physicians who participated in the 
pilot study met the same qualifications and inclusion criteria for the study as described in 
Appendix B. The pilot study provided an opportunity to make any changes or refinements 
to the survey and/or the data collection process before launching the main study.  
 Two of the four participants did not respond. The other two participants 
completed the online survey with no problems and indicated no changes were necessary 
to the survey. Two participants had no suggestions for improvement and responded the 
same, “no changes,” indicating they had reviewed the pilot study contents, had no 
problems understanding the survey questions, and had no additional comments for 




University and requested permission to conduct the main study. I was granted full 
permission to proceed with my data collection process. Walden University’s approval 
number for this study is 03-10-14-0111148 expiring March 9, 2015. I did not include the 
respondents from the pilot study in the survey pool, nor were they invited to participate in 
the actual online survey instrument. 
Data Collection 
 Qualtrics online statistical software was used to build my survey instrument, then 
securely host the online survey, and subsequently perform quantitative analysis through 
my selected criterion. A contact at a large medical facility in Stanislaus County, 
California assisted me by sending 900 invitations via a fax blast to their members that 
invited them to participate in my online survey. The survey instrument was deployed 
online on March 19, 2014 and was closed on September 25, 2014 (six months and six 
days). After screening potential candidates for eligibility to participate (described in 
Chapter 3), study participants completed the informed consent process, answered the 
survey questions, and submitted their responses electronically. I expected to meet my 
minimum sample size within 90 days; however, because of low participation numbers (N 
= 17) I consulted with my contact at the large medical facility, my committee, and the 
Walden Institutional Review Board (IRB). I requested an extension of 90 additional days 
to collect additional data. During this extension period, I was able to collect only 42 
additional surveys. I consulted again with my contact at the large medical facility, my 
committee, and Walden’s IRB committee and requested a second extension for data 




and expanded my survey collection area over to the next closest county. I was more 
purposeful in my approach and sent invitations with the online survey to specific 
organizations with similar participant criteria within San Joaquin County. The new 
survey base included agencies located within San Joaquin County, California and added 
additional 30 respondents to my pool for a grand 89 respondents.  
 My efforts to achieve the minimum sample size began with a population of (N = 
900) and expanded to (N = 2,700) potential participants, unfortunately, my efforts were 
not successful in reaching the minimum sample size for this study. My contacts within 
both counties sent each potential participant the initial invitation, which included the 
online survey link and two additional reminders to complete the survey. In spite of my 
efforts to recruit additional participants, I collected 89 surveys of which 17 were 
disqualified because they were administrators and did not meet the inclusion criteria for 
my study. Additionally, 18 other surveys were removed for due to incomplete answers 
with too much missing data to compute any research variables. I consulted with my 
committee members and the College of Health Sciences research coordinator, we decided 
to suspend participant recruitment because of constraints of time and resources, and 
established sufficient good faith effort was applied for participant recruitment. I received 
approval to proceed directly to data analysis and interpretation given my concerted efforts 
at trying to achieve the minimum sample size, and realizing that findings involved 
required cautious interpretation given the reduced power of the study to detect an effect. 
The Bonferroni adjustment is recognized to reduce the risk of type I error rates, also 




mathematical adjustment, commonly used by Epidemiologists, that provides valid and 
reliable statistical data and effect power to identify type I errors (Bender & Lange, 2001). 
While a Bonferroni adjustment is unnecessary with regard to sample size and p values 
and the Holm calculation method, also used by Epidemiologists for other studies, it may 
be more suitable for smaller sample statistical inferences (Aickin & Gensler, 1996). I 
decided to use and apply the Bonferroni adjustment to my data set based upon the 
consistent research findings on the topic of Bonferroni adjustments and the 
appropriateness for application to my findings. The data collection remained true to the 
plan as discussed in Chapter 3 and no discrepancies were further noted. In Chapter 5, I 
will discuss in detail recommendations for future researchers interested in conducting 
research with similar study subjects as this dissertation. I downloaded the final data to my 
computer for analysis. I will discuss my results next. 
Results 
Characteristics of the Study Population 
Again, I evaluated specific focused area: providers’ knowledge, attitudes and 
utilization patterns of the new NIA AD protocol examining provider perceptions and 
opinions regarding the feasibility of incorporating the new NIA AD criteria 
recommended by the NIA and Alzheimer’s Association through responses to two primary 
research questions. Because of the low return rate, both participants that were responsible 
for diagnosing Alzheimer’s disease and those who were not were included in the study. 




participants to confirm the findings. The overall sample consisted of 55 participants, 
while the subset of qualified individuals consisted of 19 of the overall 55.  
 Overall sample. Within the overall sample, the vast majority of participants 
predominantly practiced in Stanislaus County or San Joaquin County (54, or 98%). There 
were 22 physicians and 33 nurses providing completed surveys. Twenty respondents 
(36%) indicated they were responsible for making a diagnosis of AD. A majority of my 
respondents (38, or 69%) was not board certified. Of those that responded (17, or 31%) 
the 17 participants responding to the area of specialty not all could be grouped into 
similar categories because respondent’s did not further identify their area, although 
respondents were given the opportunity with option “c” as other to fill in their specialty 
did not. For example, responses could have been nurse practitioner, non-NP, LPN, etc.  
 The majority of the overall sample was not responsible for diagnosing 
Alzheimer’s patients within their role in the healthcare system (35, or 64%). The 
respondents included physicians, nurses, and nurse practitioners and as such, I assumed 
they had existing training or knowledge to be able to spot early signs of AD within the 
limits of their clinical practice. Twenty-two respondents (40%) were aware and 32 (58%) 
were not aware of the new NIA protocols. Slightly more participants were female (33, or 
60%) than male (22, or 40%). Most participants were not board certified (38, or 69%). 
The majority of participants did indicate they did not use the NIA criteria to diagnose 
Alzheimer’s disease (46, or 85%). More than half the respondents indicated they did not 
intend to use NIA criteria in the next 12 months (27, or 54%). Seventeen respondents 




specialty as those that did and identified passing boards as a gerontologist or nurse 
practitioner.  
 Of those respondents, one reported being a gerontologist; the others were board 
certified or nurse practitioners. Regarding the knowledge assessment, scores ranged from 
0 to 30 as reported from my from the ADKS survey portion of my survey. The sample’s 
scores on this assessment ranged from 13 to 28, indicating none of the participants had 
100% correct on this assessment; the maximum score was 28, or 93%. However, the 
average score was 21.31, which corresponded with 71% correct. The standard deviation 
of 2.79 indicated that much of the sample was clustered between the scores of 62% 
correct to 80% correct. The average score of 71% indicates respondents knowledge of 
AD may be lacking and thus provide an indicator for more AD training for healthcare 
providers. Table 7 presents frequencies and percentages for selected nominal variables.  
Table 7 
Frequencies and Percentages for Selected Nominal Variables (N = 55) 
Variables n % 
   
Responsible for Alzheimer’s diagnosis   
No 35 64 
Yes 20 36 
Predominant county of practice   
Stanislaus or San Joaquin County 54 98 
Tuolumne County 1 2 
Gender   
Female 33 60 
Male 22 40 
Board certified/“specialty”   
No 38 69 
Yes 17 31 




No 46 85 
Yes 8 15 
Note. Not all respondents answered questions relating to currently used and intend to use 
NIA criteria. Due to rounding error, percentages may not add up to 100. 
 
 
Participants in the overall sample ranged in age from 24 to 80, with an average 
observed age of 51.02 years (SD = 13.72). Participants had graduated between 0 and 56 
years before data collection, with an average length of 24.44 years since graduation (SD = 
15.16). Participants reported the proportion of their patients who were older than 60 
ranged between 0–100%; on average, 36.91% of participants’ patients were over the age 
of 60 (SD = 27.53). Participants were also assessed for knowledge regarding Alzheimer’s 
disease using the ADKS, and knowledge scores fell between 13.00 and 28.00. A perfect 
score was not achieved representing 30/30 questions answered correctly. The scores 
indicated a low knowledge of AD. The average score for the gathered sample was 21.31 
(SD = 2.79). Table 8 presents means and standard deviations for continuous variables 
evaluating data from 55 completed surveys. 
Table 8 
 
Means and Standard Deviations for Selected Continuous Variables (N = 55) 
Variable M SD 
   
Age 51.02 13.72 
Years Since Graduating 24.44 15.16 
Percent of Patients Older than 60 36.91 27.53 
Knowledge a 21.31 2.79 
Note. Not all respondents answered questions relating to age, years since graduation, 
percent of patients older than 60, and knowledge.  
aKnowledge was assessed using the correct results from the Alzheimer’s disease 





 Subset data. Of the 20 who responded that they were legally responsible for 
diagnosing Alzheimer’s disease, one responded that they were an RN, and was excluded 
from the subset. Of those who provided their job specialty, one was a primary care 
physician, one was an ophthalmologist, and one was an anesthesiologist. Demographic 
information for the final subset of 19 (minus the RN) responsible for Alzheimer’s 
diagnosis is presented in Table 8 below.  A majority of this subset was from Stanislaus or 
Joaquin County (18, or 95%) and were male (11, or 58%).  More of this subset was not 
board certified (13, or 68%) than were certified (6, or 32%). In addition, most did not use 
the NIA criteria at the time of data collection (14, or 74%). Demographic information for 
the subset of participants who were responsible for Alzheimer’s diagnosis are presented 





Frequencies and Percentages for Subset Sample (N = 19) 
Variables n % 
    
Predominant county of practice   
 Stanislaus or San Joaquin County 18 95 
 Tuolumne County 1 5 
Gender   
 Female 8 42 
 Male 11 58 
Board Certified   
 No 13 68 
 Yes 6 32 
Currently use NIA Criteria   
 No 14 74 
 Yes 5 26 
Note. Not all respondents answered questions relating to currently use and intend to use 
NIA criteria. Due to rounding error, percentages may not add up to 100. 
 
 
The subset of participants who were responsible for Alzheimer’s diagnosis ranged 
in age from 28 to 79, with an average observed age of 50.68 years (SD = 13.26). These 
participants had graduated between 1 and 50 years before data collection, with an average 
length of 21.74 years since graduation (SD = 14.22). Participants reported the proportion 
of their patients who were older than 60 ranged between 20–95%; on average, 42.25% of 
these participants’ patients were over the age of 60 (SD = 18.95%). Participants were also 
assessed for knowledge regarding Alzheimer’s disease using the ADKS, and knowledge 
scores fell between 14.00 and 25.00. A perfect score was not achieved representing 30/30 
questions answered correctly. The scores indicated a low knowledge of AD. The average 




standard deviations for continuous variables evaluating the subset of participants who 
were responsible for Alzheimer’s diagnosis. 
Table 10 
 
Means and Standard Deviations for Subset’s Continuous Variables (N = 19) 
Variable M SD 
   
Age 50.68 13.26 
Years Since Graduating 21.74 14.22 
Percent of Patients Older than 60 42.25 18.95 
Knowledgea 21.55 2.39 
Note. Not all respondents answered questions relating to age, years since graduation, 
percent of patients older than 60, and knowledge.  
aKnowledge was assessed using the correct results from the Alzheimer’s disease 
knowledge test used in the survey with 30 True/False responses 
 
 
I collected data using an anonymous online survey. The variables for the analysis 
were obtained through the categorical responses of the participants from the online 
survey instrument. I categorized the variables in nature from the multiple choice 
responses collected from the survey instrument. Logistic regressions were conducted 
separately on each subset of variables. For each research question, a bivariate analysis 
was conducted using chi square analysis of the six covariates.  
The following sensitivities for my data analysis were set in place as discussed in 
Chapter 3. As outlined in Chapter 3, the individual predictor and total minimum sample 
size were calculated using the G*Power 3.1 sample size calculator (Faul, Erdfelder, 
Buchner, & Lang, 2009). I selected a one-tailed test, because a one-tailed test provided 
more power than a two-tailed test and because I examined multiple factors (Faul et al., 




mostly dichotomous. Based on these calculations, and assuming a medium effect 
size (f 2 = .15) and assuming a generally accepted power of .80, approximately 97 
participants are required to discern significant relationships at the α = .05 level. 
After concluding the analysis, I conducted a post-hoc power analysis to determine 
the power of each analysis to successfully reject the null hypothesis when it is in fact 
false. Based on an alpha of .05, an achieved sample size of 55, and a normal distribution, 
power for the analyses to inform research question one ranged from .06 to .23. Using the 
same parameters, the power for the analyses to inform research question two ranged from 
.05 to .67. 
Results for the Bivariate Analyses 
Research Question 1 
 Are a physician’s background characteristics and knowledge associated with the 
physician’s use of the National Institute on Aging (NIA) criteria for the detection of 
Alzheimer’s disease (AD)? 
 To examine the relationship between background characteristics and the use of 
NIA criteria for the detection of Alzheimer’s disease, six simple logistic regressions were 
first assessed through hypothesis testing. The resulting hypotheses were: 
Subquestion 1A: Is the number of years since a physician graduated from medical 





H01A: The number of years since a physician graduated from medical 
school is not associated with that physician’s use of the NIA criteria for 
the detection of AD. 
Ha1A: The number of years since a physician graduated from medical 
school is associated with that physician’s use of the NIA criteria for the 
detection of AD. 
Subquestion 1B: Is a physician’s area of specialty associated with that physician’s 
use of the NIA criteria for the detection of AD? 
H01B: A physician’s area of specialty is not associated with that 
physician’s use of the NIA criteria for the detection of AD. 
Ha1B: A physician’s area of specialty is associated with that physician’s 
use of the NIA criteria for the detection of AD. 
Subquestion 1C: Is the percentage of patients older than 60 in a physician’s 
practice associated with that physician’s use of the NIA criteria for the detection 
of AD? 
H01C: The percentage of patients older than 60 in a physician’s practice is 
not associated with that physician’s use of the NIA criteria for the 
detection of AD. 
Ha1C: The percentage of patients older than 60 in a physician’s practice is 





Subquestion 1D: Is a physician’s gender associated with that physician’s use of 
the NIA criteria for the detection of AD? 
H01D: A physician’s gender is not associated with that physician’s use of 
the NIA criteria for the detection of AD. 
Ha1D: A physician’s gender is associated with that physician’s use of the 
NIA criteria for the detection of AD. 
Subquestion 1E: Is a physician’s age associated with that physician’s use of the 
NIA criteria for the detection of AD? 
H01E: A physician’s age is not associated with that physician’s use of the 
NIA criteria for the detection of AD. 
Ha1E: A physician’s age is associated with that physician’s use of the NIA 
criteria for the detection of AD. 
Subquestion 1F: Is a physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, associated with that 
physician’s use of the NIA criteria for the detection of AD? 
H01F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is not 
associated with that physician’s use of the NIA criteria for the detection of 
AD. 
Ha1F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is associated 




 Because six analyses were conducted on the same dependent variable (use of the 
NIA criteria for AD detection), a Bonferroni correction was applied to the resulting p 
values. The critical alpha was divided by the number of times the analyses were 
conducted on the dependent variable, and resulted in a final critical alpha of (.05/6), or 
.008. Thus, significance was determined for any model or individual predictor if the 
corresponding p value was at or below .008.  
Years since Graduation 
 First, a logistic regression assessed whether years since graduation predicted NIA 
use. The use of NIA was coded as 0 = No and 1 = Yes. The results of the logistic 
regression did not show a significant model, χ2(1) = 0.51, p = .475, Nagelkerke R2 = .02. 
This suggests that years since graduation did not predict NIA use. Table 11 presents 
results of the logistic regression. These results were replicated using the subset of 
participants who were responsible for diagnosing Alzheimer’s disease (χ2(1) = 2.30, p = 
.130, Nagelkerke R2 = .16).   
 Specialty 
 A logistic regression was conducted to assess if certification “specialty” predicted 
NIA use. NIA use was coded as 0 = No and 1 = Yes. The results of the logistic regression 
did not show significance in the full model, χ2(1) = 0.15, p = .695, Nagelkerke R2 = .01. 
Note: that the individual predictor can have a slightly different p value. This suggests that 
certification did not predict NIA use. Table 11 presents results of the logistic regression. 
These results were replicated using the subset of participants who were responsible for 




Percent of Patients Over 60 
 A logistic regression then assessed if the percent of patients older than 60 
predicted the use of NIA criteria. NIA use was coded as 0 = No and 1 = Yes. The results 
of the logistic regression did not show a significant model, χ2(1) = 1.86, p = .173, 
Nagelkerke R2 = .06. Note:  that the individual predictor can have a slightly different p 
value. This suggests that the percent of patients older than 60 did not predict NIA use. 
Table 11 presents results of the logistic regression. These results were replicated using 
the subset of participants who were responsible for diagnosing Alzheimer’s disease (χ2(1) 
= 0.47, p = .492, Nagelkerke R2 = .03). 
Gender 
 The following logistic regression assessed if gender predicted NIA use. NIA use 
was coded as 0 = No and 1 = Yes. Since gender was a nominal variable, it was dummy-
coded to have female as the reference category. The results of the logistic regression did 
not show a significant model, χ2(1) = 0.04, p = .839, Nagelkerke R2 = .00. This suggests 
that gender did not predict NIA use. Table 11 presents results of the logistic regression. 
These results were replicated using the subset of participants who were responsible for 
diagnosing Alzheimer’s disease (χ2(1) = 2.54, p = .112, Nagelkerke R2 = .17). 
Age 
 Next, a logistic regression assessed if age predicted NIA use. NIA use was coded 
as 0 = No and 1 = Yes. The results of the logistic regression did not show a significant 
model, χ2(1) = 0.67, p = .414, Nagelkerke R2 = .02. This suggests that age did not predict 




replicated using the subset of participants who were responsible for diagnosing 
Alzheimer’s disease (χ2(1) = 1.63, p = .201, Nagelkerke R2 = .12). 
Knowledge 
 The final logistic regression for Research Question 1 assessed if knowledge 
predicted NIA use. NIA use was coded as 0 = No and 1 = Yes. The results of the logistic 
regression did not show a significant model, χ2(1) = 2.53, p = .112, Nagelkerke R2 = .08. 
This suggests that knowledge of Alzheimer’s did not predict the use of NIA criteria. 
Table 11 presents results of the logistic regression.  
 This analysis was then conducted using the subset of participants who were 
responsible for diagnosing Alzheimer’s disease. Results of this analysis suggested a 
significant relationship between knowledge of Alzheimer’s, and the use of NIA criteria to 
diagnose Alzheimer’s (χ2(1) = 7.97, p = .005, Nagelkerke R2 = .47). The results suggested 
that approximately 47% of the variance in whether these participants used NIA criteria 
was accounted for by differences in their Knowledge of Alzheimer’s. However, 
assessment of the individual predictor (knowledge) using the Wald statistic did not 
suggest that knowledge was significantly predictive of NIA use (Wald z = 3.64, p = .056). 
However, these findings are possibly due to the low sample size. 
Table 11 
Results for each Logistic Regression Predicting NIA Use 
Source B SE z p OR 95% CI for 
OR 
        
Hypothesis A       
















 Certified (ref: not certified) 0.32 0.80 0.40 .692 1.37 [1.09, 1.44] 
Hypothesis C       
 Patients older than 60 under care 
of respondent 
0.02 0.01 1.37 .171 1.02 [0.99, 1.05] 
Hypothesis D       
 Male (ref: female) -0.16 0.79 -0.20 .840 0.85 - 
Hypothesis E       
 Age 0.02 0.03 0.81 .417 1.02 [0.97, 1.08] 
Hypothesis F       
 Knowledge -0.21 0.13 -1.60 .110 0.81 [0.63, 1.05] 
Note. Due to the high standard error, the 95% confidence interval could not be computed 
for gender. 
 
Research Question 2 
 Are a physician’s background characteristics and knowledge associated with the 
physician’s intention to use the National Institute on Aging (NIA) criteria for the 
detection of Alzheimer’s disease (AD)?   
 To examine the relationship between background characteristics and the use of 
NIA criteria for the detection of Alzheimer’s disease, six simple logistic regressions were 
first assessed through hypothesis testing. The resulting hypotheses were: 
Subquestion 2A: Is the number of years since a physician graduated from medical 
school associated with that physician’s intention to use the NIA criteria for the 
detection of AD? 
H02A: The number of years since a physician graduated from medical 
school is not associated with that physician’s intention to use the NIA 
criteria for the detection of AD. 
Ha2A: The number of years since a physician graduated from medical 
school is associated with that physician’s intention to use the NIA criteria 




Subquestion 2B: Is a physician’s area of specialty associated with that physician’s 
intention to use the NIA criteria for the detection of AD? 
H02B: A physician’s area of specialty is not associated with that 
physician’s intention to use the NIA criteria for the detection of AD. 
Ha2B: A physician’s area of specialty is associated with that physician’s 
intention to use the NIA criteria for the detection of AD. 
Subquestion 2C: Is the percentage of patients older than 60 in a physician’s 
practice associated with that physician’s intention to use the NIA criteria for the 
detection of AD? 
H02C: The percentage of patients older than 60 in a physician’s practice is 
not associated with that physician’s intention to use the NIA criteria for 
the detection of AD. 
Ha2C: The percentage of patients older than 60 in a physician’s practice is 
associated with that physician’s intention to use the NIA criteria for the 
detection of AD. 
Subquestion 2D: Is a physician’s gender associated with that physician’s intention 
to use the NIA criteria for the detection of AD? 
H02D: A physician’s gender is not associated with that physician’s 
intention to use the NIA criteria for the detection of AD. 
Ha2D: A physician’s gender is associated with that physician’s intention to 




Subquestion 2E: Is a physician’s age associated with that physician’s intention to 
use the NIA criteria for the detection of AD? 
H02E: A physician’s age is not associated with that physician’s intention 
to use the NIA criteria for the detection of AD. 
Ha2E: A physician’s age is associated with that physician’s intention to 
use the NIA criteria for the detection of AD. 
Subquestion 2F: Is a physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, associated with that 
physician’s intention to use the NIA criteria for the detection of AD? 
H02F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is not 
associated with that physician’s intention to use the NIA criteria for the 
detection of AD. 
Ha2F: A physician’s knowledge about AD, as indicated by his or her 
performance on the Alzheimer’s Disease Knowledge Scale, is associated 
with that physician’s intention to use the NIA criteria for the detection of 
AD. 
Years since Graduation 
 The first logistic regression assessed if years since graduation predicted Intent. 
Intent was coded as 0 = No and 1 = Yes. The results of the logistic regression did not 
show a significant model, χ2(1) = 3.17, p = .075, Nagelkerke R2 = .09. This suggests that 




regression. These results were replicated using the subset of participants who were 
responsible for diagnosing Alzheimer’s disease (χ2(1) = 0.47, p = .495, Nagelkerke R2 = 
.04). 
Certification 
 A logistic regression then assessed if certification predicted Intent. Intent was 
coded as 0 = No and 1 = Yes. Since certification was a nominal variable, it was dummy-
coded to have NO as the reference category (i.e., Yes = 1, No = 0). The results of the 
logistic regression did not show a significant model, χ2(1) = 0.13, p = .724, Nagelkerke 
R2 = .00. This suggests that certification did not predict Intent. Table 12 presents results 
of the logistic regression. These results were replicated using the subset of participants 
who were responsible for diagnosing Alzheimer’s disease (χ2(1) = 0.22, p = .641, 
Nagelkerke R2 = .02). 
Patients over 60 
 A logistic regression then assessed if percent of patients older than 60 predicted 
Intent. Intent was coded as 0 = No and 1 = Yes. The results of the logistic regression did 
not show a significant model, χ2(1) = 0.32, p = .572, Nagelkerke R2 = .01. This suggests 
that the percent of patients older than 60 did not predict Intent. Table 12 presents results 
of the logistic regression. These results were replicated using the subset of participants 
who were responsible for diagnosing Alzheimer’s disease (χ2(1) = 0.00, p = .966, 







 The next binary logistic regression assessed if gender predicted Intent. Intent was 
coded as 0 = No and 1 = Yes. Since gender was a nominal variable, it was dummy-coded 
to have female as the reference category. The results of the logistic regression did not 
show a significant model, χ2(1) = 1.82, p = .178, Nagelkerke R2 = .05. This suggests that 
gender did not predict Intent. Table 12 presents results of the logistic regression. This 
analysis was then conducted using the subset of participants who were responsible for 
diagnosing Alzheimer’s disease (χ2(1) = 4.97, p = .026, Nagelkerke R2 = .35), which did 
not indicate any relationship at the Bonferroni corrected alpha level of .008. 
Age 
 A logistic regression next assessed if age predicted Intent. Intent was coded as 0 = 
No and 1 = Yes. The results of the logistic regression did not show a significant model, 
χ2(1) = 0.02, p = .894, Nagelkerke R2 = .00. This suggests that age did not predict Intent. 
Table 20 presents results of the logistic regression. These results were replicated using 
the subset of participants who were responsible for diagnosing Alzheimer’s disease (χ2(1) 
= 0.25, p = .618, Nagelkerke R2 = .02). 
Knowledge 
 The final logistic regression assessed if knowledge of Alzheimer’s predicted 
Intent. Intent was coded as 0 = No and 1 = Yes. The results of the logistic regression did 
not show a significant model, χ2(1) = 0.06, p = .800, Nagelkerke R2 = .00. This suggests 




These results were replicated using the subset of participants who were responsible for 
diagnosing Alzheimer’s disease (χ2(1) = 0.35, p = .556, Nagelkerke R2 = .03). 
Table 12 
Results for Each Logistic Regression Predicting Intent 
Source B SE z p OR 95% CI for 
OR 
        
Hypothesis A       
 Years Since Grad -0.03 0.02 -1.71 .087 0.97 [0.93, 1.00] 
Hypothesis B       
 Certified (ref: not certified) 0.22 0.63 0.35 .724 1.25 - 
Hypothesis C       
 Patients Older than 60 under 
care of respondent 
0.01 0.01 0.56 .573 1.01 [0.99, 1.03] 
Hypothesis D       
 Male (ref: female) 0.78 0.58 1.34 .181 2.18 - 
Hypothesis E       
 Age -0.00 0.02 -0.13 .894 1.00 [0.96, 1.04] 
Hypothesis F       
 Knowledge 0.03 0.10 0.25 .800 1.03 [0.84, 1.25] 
Note. Due to the high standard error, the 95% confidence interval could not be computed 
for certification or gender. 
Summary 
A complete analysis of the data provided over the course of six months was 
conducted as described in Chapter 3 first using a correlational and a bivariate analysis 
statistic to assess the data for possible correlation. Consequently, further analysis was 
conducted evaluating the data for possible bivariate and multivariate correlations. There 
was no statistical correlation using a multivariate analysis and determined no further 
reporting was indicated. My next step was to apply a Bonferroni correction as discussed 
in Chapters 3 and 4. I applied the Bonferroni correction for the original .05 alpha. The 




statistical correlations between physicians’ background characteristics/AD knowledge 
and their use of and intention to use the NIA criteria. I will discuss my interpretation of 




Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
 Clinicians rely on a patient’s history and physical examination when formulating 
their diagnoses. Clinicians often do not diagnose dementia during patient visits and 
approximately half of the patients with dementia symptoms ranging from mild to 
moderate have never received diagnosis of dementia or Alzheimer’s disease (AD) from a 
clinician (USPSTF; as cited in Boustani, Peterson, Harris, & Lohr, 2003).  Primary care 
clinicians need a screening test with measurable outcomes when constructing their patient 
diagnosis and treatment plans, one that could be used during a single office visit and 
correlated to the DSM-IV-TR (Boustani et al., 2003).  
Still, a recent study recommends three such in office test for the early diagnosis of 
AD leading toward other AD tests such as the Clock Draw test (CDT, Jack et al., 2011). 
In office tests such as the Mini-Cog uses the components of the MMSE that include 
specifically the three-item recall, testing the person for the ability to recall three words 
after roughly 1 minute, and a CDT (Kamenski et al., 2009). Jack et al., (2011) identified a 
four-item recall test. Primary care clinicians need a screening test with measurable 
outcomes, which could be used during a single office encounter and correlated to the 
DSM-IV-TR (Boustani et al., 2003).  
According to estimates (Christensen & Lin, 2007), there are over 5 million 
diagnosed cases of AD in the United States and that number could reach or 
exceed 15 million by 2050 according to studies indicating AD may be 




2007). Furthermore, because AD may be underreported AD can be diagnosed in 
the early stages of the disease within the primary care setting (Christensen & Lin, 
2007 and Fearing et al. 2007). Additionally, the rates of AD diagnoses will 
increase annually as the elderly population in the United States increases 
(Christensen & Lin, 2007).  Lindesay et al. (2010) reported that physicians still 
use the word senile dementia when diagnosing a patient with AD-type dementia. 
However, the current literature states that, to make an accurate diagnosis, an 
autopsy must be performed and brain tissue examined under a microscope 
(Christensen & Lin, 2007). In summary, because AD may go underreported, may 
be misdiagnosed, and is not clearly defined as seen in the DSM-IV-TR then 
additional research to choreograph medical terminology associated with the 
diagnostic term “AD”. 
In this study I sought to understand how many physicians are aware of the new 
NIA criteria and if they intend to use them in the future. I further examined physicians 
patterns of use of the new NIA AD criteria. What is still lacking is consensus on the exact 
symptoms of AD that GPs can use to diagnose early-, middle-, and late-stage AD in their 
patients.  No studies have been conducted exploring physicians use or willingness to use 
the new NIA AD criteria (Jack et al., 2011). 
The demographics used in this study did not result in one or more demographic 
being statistically sensitive enough to predict which might predict future use of the new 
NIA criteria. The lack of respondents and completed surveys affected my ability to 




survey despite tireless efforts to achieve the minimum sample size. Specific 
demographics such as the number of years since graduating from medical school, area of 
specialty, percentage of patients over age 60 years, physician gender, physician age, and 
knowledge about AD, as indicated by performance on the ADKS were examined. The 
framework for this chapter includes a discussion of the interpretation of the findings, 
limitations of the study, recommendations for action, implications for social change, and 
ends with the chapter conclusion. The purpose of this research investigated physician use 
of the NIA AD protocol through a series of two primary research questions concerning 
the relationship between various physician background characteristics and use of and 
intention to use the NIA criteria for all-cause dementia and the early detection of 
Alzheimer’s disease. Next, I will present my interpretation of the findings. 
Interpretation of the Findings 
My interpretation of the key findings is presented with caution due to the limited 
sample size being reported because the findings did not reach the minimum required for 
any of the analyses to be statistically significant for a multivariate analysis.  The results 
were sound for a correlational and a bivariate analysis.  The following discussion 
represents my interpretation of my findings.  
My statistical analysis indicated there are no independent indicators clearly 
predicting if or when a physician will or will not use the NIA diagnostic criteria for 
diagnosing a patient with AD. Likewise, the U.S. Preventive Services Task Force 
(USPSTF; as cited in Boustani, Peterson, Harris, & Lohr, 2003) reported insufficient data 




patients, aged 65 and over, with dementia symptoms. When examined separately none of 
the six (A-F) hypothesized factors were related to the use of NIA criteria to diagnose 
Alzheimer’s disease. The six analyzed factors included years since graduation, 
certification, percent of patients older than 60, gender, age, and knowledge about 
Alzheimer’s disease. The results for each bivariate analysis were not significant at the α = 
.05 level, or at the Bonferroni corrected level of α = .008. As such, none of the analyses 
could be used to describe the strength or direction of bivariate relationships between any 
factor and the use of NIA criteria. The results from Chapter 4 confirms previous research 
presented in Chapter 4 in that no one variable or combination of multivariables presented 
a model to predict the use of the new NIA AD diagnostic protocol criteria. Additionally, 
the small sample size greatly reduced the possibility of finding associations, which may 
have been found in a multivariate environment if indeed there were some associations.  
My descriptive findings demonstrated that the average score on the ADKS was 
about 20–30 questions correct and that there was a wide range of scores. Also, when  
examined separately, none of the six hypothesized factors were related to the intention to 
use of NIA criteria to diagnose Alzheimer’s disease or, relatedly, the intention to not use 
NIA criteria. The six analyzed factors included years since graduation, certification, 
percent of patients older than 60, gender, age, and knowledge about Alzheimer’s disease. 
The results for each bivariate analysis were not significant at the α = .05 level, or at the 
Bonferroni corrected level of α = .008. As such, none of the analyses could be used to 




intent to use of NIA criteria in the future confirming the published literature, i.e., 
(USPSTF; as cited in Boustani, Peterson, Harris, & Lohr, 2003).  
I examined  all variables simultaneously. The goal of these analyses was to 
determine if the full set of factors was able to significantly predict the use, or intent to use 
NIA criteria. Though each variable was assessed independently, the inclusion of multiple 
variables typically contributes to increased predictive ability in a regression model 
(Pallant, 2010). As such, one model was conducted for each dependent variable (i.e., use 
of NIA criteria and intention to use NIA criteria). Intention to use the NIA criteria was 
assessed to examine RQ2,the intention to use.  
I calculated my statistical analysis using a binary logistic regression model to 
predict significan trelationships within the data collected from my survey instrument then 
univariate to predict significant relationships within the data collected from my survey 
instrument. Results from the univariate model and  binary logistic regressions did not 
indicate any significant relationship between the factors of interest and either the use of 
NIA critieria or the intention to use NIA critiera. When I further evaluated the data using 
a univariate model the data  were non-significant at both the critical alpha of α = .05. 
When I applied the Bonferroni adjustment setting the alpha, α = .008, my results 
indicated the number of years since graduation, certification, percentage of patients older 
than 60, gender, age, and knowledge of Alzheimer’s disease were not significant 
predictors. I used critial alpha of α = .05 and also applied the Bonferroni correction alpha 
of α = .008 when I interpreted the results from the models. The statisical models 




these levels in that the variables were non-significant for further interpretation and 
possible predictions. 
Limitations of the Study 
Results of this study should be interpreted with caution. Traditional caution for a 
binary logistc regression suggests that for each predictor variable, the sample should 
include responses from at least 10 participants with “yes” responses to the dependent 
variable, and 10 participants with “no” responses. For each simple binary logistic 
regression, only approximately 20 participants were necessary as a minimum, however, 
for the larger models in the multivariate analyses, up to 120 participants may have been 
necessary to determine statistical significance (Peduzzi et al., 1996). Other suggestions 
for sample size requirements, even those for simple binary regression, suggest up to 300 
participants minimally (Hsieh, Block, & Larsen, 1998). The statistical models presented 
in Chapter 3 indicated a G*Power sample size of 97 was needed for a multivariate 
analysis and my final collection of survey respondants would have been 97 or greater. As 
discussed in previous chapters, a multivariate was not statistically supported with ony 89 
respondents. However, a Priori Power analysis was conducted and indicated a total 
sample size of 16 was required and 89 surveys were collected. After cleaning the data I 
removed 34 surveys the sample size. The 34 surveys were removed because they were  
not healthcare providers or did not provide completed surveys. My critieria for what 
constituted a completed survey filtered to ensure the respondent was a healthcare 




such, the reporting sample size of 55 participants may have been insufficient to determine 
significance where it did exist.  
A clear limitation of this survey was that respondents did not clearly indicate they 
were a physican, indicate they were board certified and if so which board they had 
passed, or nurse and if a nurse what level of nursing degree they held, i.e., LPN, RN, or 
Nurse Practionier and of those 20 repondents they did not complete the entire survey. My 
survey was designed with filters to prescreen respondents at the onset of the survey based 
upon initial repsonses. For example, if a respondent answered they were a technician or 
administrator by profession they were automatically disqualified and exited the survey. 
However, if the respondent indicated they were either a physician or nurse by profession 
the online survey automatically advanced them to the next question. A better designed 
survey may have captured the actual number of actual physicians, type of physicians/area 
of practice, certification, and or specialty and or specific number of nurses indicating 
their specific nursing license/area of practice. This question had 17 positive responses. 
One respondent indicated she/he was a gerontologist, another optomitrist, and others 
were nurse practionioners.  
However, one question within the survey did ask about one’s advanced training, 
are you board certified and if so please indicate by writing in your response. Additionally, 
each of the demographic questions and subsequent questions allowed the respondent to 
“fill-in” or indicated an area for additional write in responses. Another limitation of the 
study involved external validity due to the utilization of a convenience, or non-random 




Convenience sampling was selected because the sample was taken from one geographic 
area (two northern California counties).  I am aware that findings from this study may not 
be applicable to other physicians in California, in other states and localities, as 
demographic factors may skew data in some unknown manner, however, I intentionally 
selected my six variables as they were supported by the literature review from studies 
presented in Chapter 2. 
Recommendations for Action 
An interesting outcome observed in Table 11 found in Chapter 4 regarding 
knowledge of AD—hypothesis F approached significance.  The beta of (-0.21) predicts 
the opposite of the p value.  In other words as the p value increases by one so should the 
beta—this is an anomaly requiring further research.  This is interpreted as knowledge of 
AD increases the intent of using the New NIA AD diagnostic criteria decreases even after 
a Bonferroni corrected level of α = .008 and counter intuitive.  Furthermore, this 
discovery may correlate to the actual number of doctors and nurses completing my 
survey.  My recommendation for future research is to examine this potential predictor in 
greater detail.   
The results of my study advances the current knowledge for future studies 
examining which factors may influence the use of new diagnostic tools for diagnosing 
patients with early symptoms of AD and the implementation of the NIA AD criteria. 
Despite the limitations of a low response rate, new information is valuable for future 
researchers in that this study provides important and initial ground work for continued 




potential criteria which may predict physicians intention to use or not to use new 
diagnostic criterion for the early diagnosis of AD.  
I advocate the following modifications for future researchers exploring the same 
topics as I. I would first address the need for increasing and obtaining more respondants 
to the survey instrument. I sought out several key personnel and for one reason or another 
they backed out. My recommendation is to work with key personnel that advocate the 
need for continuing research to advance knowledge on the three research questions 
presented herein. One might seek out multiple key advocates from three to five counties 
with similar demographics. Additionally, one might consider using a paper survey versus 
an online survey following a presentation on a topic such as new criteria for diagnosing 
AD. A pre-test and post test could successfully evaluate pre and post knowledge, 
attitudes, and behaviors for patients with AD and those attitudes and behaviors for 
paitents with AD. I would also revise the title of my survey to sound more inclusive of a 
wide range of eligible healthcare providers and remove the wording gerontoligist. 
Additionally, I would refine my demographic questions at the onset of the survey to 
inquire more detials about respondent’s level of training, certification, and speciality 
degrees/boards.  
Because there was such a low response rate to my survey instrument I would 
recommend future researchers continue this initial work to seek out which if any 
predictors can successfully predict when physicians’ will or will not use the NIA 
diagnostic criteria. As continued research comes closer to discovering the etiology of AD 




would further recommend continued training on current diagnostic methodologies in the 
form of continuing education and in-service training. For example, a pretest on the 
subject of diagnostic criteria could be distributed to a group of attendees. The pretest 
could then be collected followed by a presentation regarding NIA diagnostic criteria for 
diagnosing AD. Following the presentation, one could then reassess the attendees and 
evaluate newfound knowledge, change in attitudes regarding AD, and evaluate a change 
in behaviors toward the new diagnostic criteria (Wright et al., 2011). 
Additional research is recommended using the same survey instrument herein and 
build upon my findings to continually advance the discoveries elucidated. Additionally, 
future studies should strive for an increased sample size for greater statistical power 
analysis. Data from a larger respondent pool may provide clear evidence with which to 
predict physicians’ knowledge, attitudes, and behaviors about AD criteria. While there is 
limited data from my study regarding providers knowledge, attitudes, and beheaviors of 
AD I would suggest one could possibly develop an intervention program involving a 
pretest, training on AD diagnostic criteria, and post test to assess learning outcomes 
(Davis, et al., 1999). The learning outcomes could then be assessed and matched with a 
training program and potentially linked to a policy and/or procedure implementing new 
AD diagnostic criteria. I would also recommend the use of Roger’s diffusion of 
innovation theory to implement a change in policy and/or procedures within an 
organization. Rogers’s (2003) diffusion of innovations (DOI) theory is appropriate to use 
for implementing change in knowledge. As previously recommended, a partnership with 




recommended for closing the gap in AD knowledge within an organization as discussed 
in Chapter 2.  
I further recommend a study expanding the new knowledge herein to evaluate the 
source documents used by healthcare providers when making a diagnosis of AD. For 
example, exploration of physicians use of desktop references, training in medical school, 
specialty training, and or use of the International Classification of Diseases (ICD) and 
DSM-IV-TR is recommended. The use of the diagnostic term senile dementia used in the 
DSM IV falsely promotes the notion that dementia naturally occurs as one ages. Boustani 
et al. (2003), reported the many benefits of early detection of AD within a physicians’ 
office and that following an interview and clinical examination by a physician could be 
accomplished within the guidelines of the DSM-IV-TR There is an established 
partnership with the NIA and the Alzheimer’s Association, which published new criteria 
for diagnosing patients with dementia of the AD type symptoms almost 30 years ago. 
Additionally, respondents to my survey instrument are not fully aware of the new NIA 
AD protocols and updates. In addition, none of my respondents indicated which if any 
protocols they followed for making a diagnosis of AD and a topic for future researchers 
to explore. I reported in Table 7, 36% of my respondents were responsible for making an 
AD diagnosis and were unaware of the new NIA criteria.  
What may be lacking is an alignment or collaboration between the current 
version/edition of the ICD, use of the current version/edition of the DSM, which 
physicians may reference to diagnose patients with AD and consistent guidelines for 




recommend an alignment between ICD, DSM, and NIA align terminology, definitions, 
and codes found in both the ICD and DSM with a future study to discover additional 
associations, benefits, and or correlations especially regarding AD.  
Implications for Social Change 
The key findings and recommendations for action presented here may have 
significant implications for social change. Healthcare providers need more training 
regarding AD symptoms, presentation of signs of AD, and earlier diagnosis to improve 
the diminishing lifespan of those afflicted with this deadly disease. , As presented in 
Chapter 2 and from the recommendation discussed in recommendations for Key Finding 
3, physicians and the healthcare community at large need to develop consistent 
terminology for the various types of dementia and dementia of AD. 
As such, the medical community could benefit from aligning their desktop 
reference and terminology to accurately describe, code, and reference AD. An alignment 
or collaboration is highly recommended between the current version/edition of the ICD 
and the current version/edition of the DSM, which physicians reference to diagnose 
patients with AD. The passé use of the diagnostic term senile dementia as used in the 
current edition DSM IV falsely promotes the notion that dementia naturally occurs as one 
ages and both the ICD and DSM should parallel one another. I developed the acronym 
Classic Alzheimer’s Disease Symptoms (CADS) and defined CADS in Chapter 2 as a 
way to refer to patients with dementia of the AD type. The social change and potential 
implication may advance the use of diagnostic phrase, “Classic Alzheimer’s Disease 




or even “being senile.” Rather than labeling a living patient with AD, I would 
recommend referring to living patients with dementia of the AD type as having (CADS).  
Until the healthcare sector has a biomarker and begins early testing for signs and 
symptoms of AD as recommended by the NIA and Alzheimer’s Association, we will 
continue to see misdiagnosed patients and under reporting of AD (USPSTF; as cited in 
Boustani, Peterson, Harris, & Lohr, 2003). Furthermore, close coordination with the 
World Health Organization, DSM, and ICD is needed to unite physician desktop 
references such as the DSM and ICD also used by both insurance companies in the 
United States and billing coding specialists to complete insurance claims for patient 
treatment; currently a gap exists as identified and discussed in Chapter 2.  
Significance 
 The U.S. National Institute on Aging ranked AD as the sixth most deadly disease 
Alzheimer’s Association (2012a).  The benefits of early detection and accurate diagnosis 
of AD, like many other diseases, include disease management and improved quality of 
life. An accurate and early diagnosis may also decrease stress for those seeking a reason 
for loved ones’ sudden changes in personality, mood, activities, and behavior. An early 
diagnosis of AD may thus help ease tensions within a family.  
 My study may lead to social change by promoting awareness of the importance 
for early AD diagnosis and the use of new diagnostic guidelines and materials such as the 
NIA criteria. Accurate diagnosis may assist families in reviewing finances, legal 
planning, discussing home and long-term care alternatives, and evaluating safety 




to implement routine procedures for the detection of possible dementia in primary care 
patients during office and clinic visits. Additionally, this study may illuminate the needs 
and benefits for early diagnostic evaluations for persons suspected of exhibiting AD 
symptoms, partner with those who are likeminded to provide care planning at the earliest 
possible time following a diagnosis, and document the diagnosis and care plan in a 
person’s medical record (Attea & Johns, 2010).  
Conclusion 
Patients and/or family members caring for a loved one with CADS may initially 
seek help from their primary care physicians (PCPs) (Leifer, 2009). At this time, there is 
no cure or known cause for AD. Furthermore, AD cannot be used as a diagnosis for the 
living because there is no definitive diagnostic biomarker. Currently, after a patient dies 
when an autopsy is performed to examine brain tissue and during the autopsy, the results 
of the autopsy are conclusively used describing the cause of death due to AD or other 
causes (Christensen & Lin, 2007). Okie (2011) reported that some physicians and 
agencies avoid using a diagnosis of AD. An accord is lacking regarding early diagnostic 
criteria and the exact symptoms of Alzheimer’s disease that physicians’ use to diagnose 
AD patients. In the last three years, Jack et al. (2011) co-authored a study with the 
Alzheimer’s Association, which undertook significant efforts to revise previous 
diagnostic criteria for physicians’ to use when evaluating patients with dementia type 
AD. An in office test may help physicians detect the early symptoms of AD based upon 
new National Institute of Aging criteria. Therefore, it is important for PCPs to be familiar 




My study explored the patterns of use related to the new National Institute of 
Aging Alzheimer’s disease protocol was conducted because no other researcher to date 
has explored this area. The findings support the need to improve primary care providers’ 
initial diagnostic skills for evaluating dementia/AD patients including the use of the new 
NIA criteria. I encourage future researchers to conduct a qualitative study to explore why 
the clinicians do not intend to use the NIA criteria and to learn what it will take to get 
clinicians to adopt the new NIA AD criteria. I greatly hope my findings advance the 
current knowledge and understanding of Alzheimer’s disease. At the very least, I hope I 
have inspired future researchers to pick up where I left off. 
In summary, doctors can benefit from additional AD knowledge training, using a 
standardized in office test to screen patients with AD symptoms, and routine diagnostic 
criteria from the NIA is available for doctors to reference for all stages of AD in an 
overarching goal for earlier detection of Alzheimer's disease and treatment of AD. Until a 
cure for AD is discovered earlier, detection of AD symptoms is indicated and early 
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Appendix B: Alzheimer’s Disease Survey 
Introduction 
Hello and thank you for volunteering about 15 – 20 minutes to complete 
the survey. You were selected as a potential participant in this study because you 
are thought to be involved in direct care and work with patients diagnosed with 
dementia. This study is being conducted by a researcher named Richard Schultz, 
who is a doctoral student at Walden University. 
 
Instructions: This is an online survey. The survey will take you though a 
pre-qualification process to ensure the survey instrument itself is accessed by 
appropriate healthcare providers. Please read the instructions carefully for each 
section. Please proceed. 
 
 





Alzheimer’s Disease Survey Pre-qualification Questions 
 
Instructions: Congratulations and welcome to the pre-qualification 
questions. There are three questions that will screen for appropriate respondents to 
this survey. The survey will take you though a pre-qualification process to ensure 
the survey instrument itself is accessed by appropriate healthcare providers. 
Please read the instructions carefully for each section. Please answer the 
following three questions.  
 





e. __Other, please describe 
 
2. In your role within the healthcare system are you medically and legally 




3. Which county do you predominantly practice? 
a. __Tuolumne County 
b. __Stanislaus County 
c. __Sonoma County 
d. __Sacramento County 
 
*Note: If the respondent replied b, c, d, or e to question #1 then the 
respondent does not meet the criteria to continue and is taken to the end of 
the survey and thanked for their time. 
 
*Note: if the respondent replied b to question #2 then the respondent is not 
qualified to continue and is taken to the end of the survey and thanked for 
their time. 
 
*Note: if the respondent replied a, c, or d to question #3 then the respondent 
is not qualified to continue and is taken to the end of the survey and thanked 
for their time. 
 





Survey Pre-qualification Ineligible Page 
 
Thank you for answering the survey pre-qualification questions. Unfortunately, 
you do not meet the selected criteria necessary to continue with the remaining survey 
questions. We appreciate your time and continued dedication to Alzheimer’s patients, 
their families, and caregivers.  
Instructions: Although you do not meet the criteria to proceed with the 
rest of the survey, we ask you to click on the hyperlink below to learn more about 
Alzheimer’s disease, new criteria released by the National Institute of Aging, and 






Only if the respondent chose response “A” in question #1, responded “A” to 
question #2, and responded “B” to question #3 then the surveyor may 
proceed to the Survey Consent Form. 
 
 





Alzheimer’s Disease Survey Consent Form 
 
Congratulations! You successfully qualified to complete the Alzheimer’s 
Disease Survey. Based on your answers to the previous three questions you are 
ready to start the survey. But first, you will need to familiarize yourself with the 
following consent form.  
 
You were selected as a potential participant in this study because you are a 
direct care staff working with patients diagnosed with dementia. Please read this 
form and ask any questions you have before agreeing to be part of the study. This 
study is being conducted by a researcher named Richard Schultz, who is a 
doctoral student at Walden University. 
 
Instructions: Congratulations and welcome to the consent form. Please 
read the consent form to continue and please fill in and complete all responses to 
the following fields. After completing the consent form, please click the “next” 




The purpose of this study investigates what effect Physicians Knowledge, 
Attitudes and Utilization Patterns are in relationship to the new National Institute 




If you agree to be in this study, you will be asked to: 
• Sign and return this form directly to the researcher 
• Complete a short demographic form, followed by a survey.  
• The survey is the Alzheimer’s Disease Knowledge Scale, consisting of 30 
items.   
o Voluntary Nature of the Study:  Your participation in this study is 
voluntary. This means that everyone will respect your decision of 
whether or not you want to be in the study. If you decide to join the 
study now, you can still change your mind later. If you feel stressed 
during the study you may stop at any time. You may skip any 
questions that you feel are too personal.   
o Risks and Benefits of Being in the Study: There are no physical risks 
and no benefits to participating in the study. Should there be any 
emotional upset while completing the surveys, participants can stop 
and decide not to continue with study or come back at a later time to 
complete the surveys.  
o Compensation:  No compensation will be available for participating 




o Confidentiality:  Any information you provide will be kept 
confidential. The researcher will not use your information for any 
purposes outside of this research project. Also, the researcher will not 
include your name or anything else that could identify you in any 
reports of the study.   
o Contacts and Questions:  The researcher conducting this study is 
Richard Schultz. The researcher’s faculty advisor is Dr. Richard 
Jimenez. You may ask any questions you have now. Or if you have 
questions later, you may contact the researcher at 
Richard.Schultzjr@waldenu.edu or the advisor at 
Richard.Jimenez@waldenu.edu. 
 
The researcher will email and/or you may download a copy of this form to keep. 
 
 
Statement of Consent: 
 
I have read the above information. I have received answers to any questions I 
have at this time. I am 18 years of age or older, and I consent to participate in the 
study. 
 
Printed Name of Participant _________________________________________ 
 
 
Participant’s Written Signature ___________________________________ 
 
 
Researcher’s Written Signature ___________________________________ 
 
 
Note: The respondent cannot continue unless the consent form has been 
reviewed (indicated by clicking on a radio button) indicating acceptance and 
completion allowing the participant to proceed. 
 
 






Part one is comprised of 8 background and demographic questions.  
 
Part two is comprised of 30 brief questions (True and False), which ask 
specific knowledge questions about Alzheimer’s disease and pose various 
statements. It’s important to indicate an answer for every statement, even if you’re 
not completely sure of the answer. 
 
Instructions: Congratulations and welcome to the Background and 
Demographic Information portion of the survey. Please read each question and 
either fill in the answer or select the appropriate response from the choices below. 
After completing this section, please click the “next” button to proceed indicating 
you are ready to continue to the next section of the survey.  
 
 
Background Questions and Demographic Information (Part 1) 
 
1. How old were you on your last birthday (please write in):_____________.  
 
2. What is your gender?  
a. __Male  
b. __Female 
c. __Other, please write in:________________________________. 
 
3. How many years ago did you graduate from medical school? (please write 
in)_________. 
 
4. Are you board certified? If so, in which specialty are you certified? 
a. __Yes, (please write in):________________________________. 
b. __No 
 
5. Do you use the new National Institute of Aging protocol for early 
diagnosing Alzheimer’s patients? 
a. __Yes 
b. __No 
c. __Other: (please write in):____________________________________. 
 
6. If you do not use the National Institute of Aging protocol for early 
diagnosing of Alzheimer’s patient’s will you use the new protocol in the 
next 12 months? 
a. __Yes 
b. __No 






7. If you do not intend to use the new NIA AD protocol, are you aware of the 














   
 









Alzheimer’s Disease Knowledge Scale (Part 2) 
 
 
Instructions: Congratulations and welcome to the Alzheimer’s Disease 
Knowledge Scale portion of the survey. Below are 30 statements about 
Alzheimer’s disease. Please read each statement carefully and indicate whether 
you think the statement is true or false. If you aren’t sure of the right answer, 
make your best guess. It’s important to indicate an answer for every statement, 
even if you’re not completely sure of the answer. After completing this section, 
please click the “next” button to proceed indicating you are ready to continue to 
the next section of the survey.  
 
 
1. True/False. People with Alzheimer’s disease are particularly prone to 
depression. 
 
2. True/False. It has been scientifically proven that mental exercise can prevent 
a person from getting Alzheimer’s disease. 
 
3. True/False. After symptoms of Alzheimer’s disease appear, the average life 
expectancy is 6 to 12 years. 
 
4. True/False. When a person with Alzheimer’s disease becomes agitated, a 
medical examination might reveal other health problems that caused the 
agitation. 
 
5. True/False. People with Alzheimer’s disease do best with simple, instructions 
given one step at a time. 
 
6. True/False. When people with Alzheimer’s disease begin to have difficulty 
taking care of themselves, caregivers should take over right away. 
 
7. True/False. If a person with Alzheimer’s disease becomes alert and agitated 
at night, a good strategy is to try to make sure that the person gets plenty of 
physical activity during the day. 
 
8. True/False. In rare cases, people have recovered from Alzheimer’s disease. 
 
9. True/False. People whose Alzheimer’s disease is not yet severe can benefit 
from psychotherapy for depression and anxiety. 
 
10. True/False. If trouble with memory and confused thinking appears suddenly, 





11. True/False. Most people with Alzheimer’s disease live in nursing homes. 
 
12. True/False. Poor nutrition can make the symptoms of Alzheimer’s disease 
worse. 
 
13. True/False. People in their 30s can have Alzheimer’s disease. 
 
14. True/False. A person with Alzheimer’s disease becomes increasingly likely 
to fall down as the disease gets worse. 
 
15. True/False. When people with Alzheimer’s disease repeat the same question 
or story several times, it is helpful to remind them that they are repeating 
themselves. 
 
16. True/False. Once people have Alzheimer’s disease, they are no longer 
capable of making informed decisions about their own care. 
 
17. True/False. Eventually, a person with Alzheimer’s disease will need 24-hour 
supervision. 
 
18. True/False. Having high cholesterol may increase a person’s risk of 
developing Alzheimer’s disease. 
 
19. True/False. Tremor or shaking of the hands or arms is a common symptom in 
people with Alzheimer’s disease. 
 
20. True/False. Symptoms of severe depression can be mistaken for symptoms of 
Alzheimer’s disease. 
 
21. True/False. Alzheimer’s disease is one type of dementia. 
 
22. True/False. Trouble handling money or paying bills is a common early 
symptom of Alzheimer’s disease. 
 
23. True/False. One symptom that can occur with Alzheimer’s disease is 
believing that other people are stealing one’s things. 
 
24. True/False. When a person has Alzheimer’s disease, using reminder notes is 
a crutch that can contribute to decline. 
 
25. True/False. Prescription drugs that prevent Alzheimer’s disease are available. 
 
26. True/False. Having high blood pressure may increase a person’s risk of 





27. True/False. Genes can only partially account for the development of 
Alzheimer’s disease. 
 
28. True/False. It is safe for people with Alzheimer’s disease to drive, as long as 
they have a companion in the car at all times. 
 
29. True/False. Alzheimer’s disease cannot be cured. 
 
30. True/False. Most people with Alzheimer’s disease remember recent events 
better than things that happened in the past.  
 
Please click “Next” to continue. 
 
Thank you for completing the survey you and you are finished with the 
survey 
 
Note: This concludes the survey, which includes both parts 1 and 2. Thank 
you for your assistance. If you would like to learn more about Alzheimer’s 
disease, new criteria released by the National Institute of Aging, and additional 





Click Here if you would like to have a copy of the Consent Form emailed to you. 












Appendix C: Certificate of Completion – “Protecting Human Research Participants” 
 
 
 
 
 
